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Commercial content moderators (CCM) review and remove controversial content from social 
media platforms, leading to potentially adverse mental health effects through secondary trauma 
exposure. Due to the problematic nature of their work, a U.S. based company hired mental health 
clinicians to design and instruct a resiliency program, developed based upon the psychological 
resilience literature. Regrettably, there is scarce peer-reviewed literature providing guidelines for 
best practices in program development or evaluations specific to this population to evaluate the 
a  c . T ,   a   the resiliency program 
provided to CCM workers predicted resilience and well-being outcomes by use of the 10-item 
Connor-Davidson Resilience Scale (CD-RISC 10) and the Professional Quality of Life Scale 
(ProQOL) when compared to a control group. Furthermore, whether increases in the frequency 
of attendance by mandating weekly training would increase resilience and well-being. The 
analyses consisted of two historical data sets with 497 teammates in data set one and 361 in data 
set two. Results found significant predictors for resilience when comparing subjects offered 
a      c . T   a  a    c  c  








were found, indicating that additional factors were stronger predictors in the variation of scores. 
Results of the CD-RISC 10 and the ProQOL found no significant differences between periods 
before and following mandated attendance, aligning with prior research that increased training 
does not correlate within increased well-being or resilience.  
Ke ords:  P c ca  c , c  a , -b ,  
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Rationale and Justification of the Stud  
M a  a  c c a  a  a    a  ac   b  
 c  a      a  a  ac  ca   c  
cc a a   (S   a ., 2020). S a    a  c  ca  a   c a  
c b   b , c a  a , a  c a  a a c . C  a c  
 a  cc a a   c a    a , c   a  
a , ba   a  a '  a a a     (R   a ., 2015). A  c  a  
2012,  a   a  - a   a   b  40% c  2007,  ab  
a  ca a  b  25%, a  a b   a   (H   a ., 2012; J c   
a ., 2018). T  cc a a   ca  cc   a   ,  
    b   a a c c , c  a  c c a  c  
a  (CCM) , ac  a  a  a    a  a  c b  
(W , 2019). R  c  a  c  c  b   a a cc c   
a    (R   a ., 2015). 
 I  a  a     a c    , c  c a  a  c a  a 
  CCM a   c  a   c a  c  a  a     
 a   ac   a   b  a  . R ab ,  b a   
    a  a  a a , ca   a   
(R b , 2019). P  a   a  c a    a  a  a a  a  a  
a a    c   a   c    a a c . T  
a  ca  a   a c   c   a  a , , a  








 a  a  c    ac  (N , 2019; B   a ., 2014).  
C a   a   c   a c a    CCM  
a  a   b  c a   c      a  a  
 b  a  a  c c a . R c  a  c   c , a  , a  
c   c , a  c , a  - a a c  (S b , 2004). T  
a  a    a   c a    a a   a  a   c  
 a      ac . A  a      
c   ac  -b  a  c  ,  a    c a  
a  , a ca    a  a , a  a  ab c   a  
ca  a a  a  (L   a ., 2014; R b   a ., 2015). T  ac   
a a a  a  a a c  ca    a a   c  a  
c  a    c  a  a   a  CCM a  ca  . 
Problem Statement  
A   a 2019 , 2.95 b   ba   c a  a, a  b  2023  
b  a  c   c a   3.43 b . G    U  S a   a   b  
b  c  a  a  acc b , a   69%   US a  acc  a  
 a   c a  a. W   a  a  a  a  b   a a  
 a  a a  b  b  c a  a a , a b    b a  c   
a  a  ab  c  (C , 2019).  
T   a  , K  Ca a , V c  P   T  a  Sa   
G ,  a   2017, G '  a   2.3 b  a  a  b c  79  
a  a   b   a '  c     a  a a - a  . 








 c . S   a  Y b   7   a  b c  224  
c  (Ca a , 2019). F a , Fac b  a    a   2018;  c a  
 837  c    a a   a  a , 21  c   a a  
c  a  , 3.5  c a   c , a  2.5  c a  a  
c  (R , 2018). I  a  a     a c    , c  c a  a  
c a  a   CCM a   c  a   c a  c  a  a  
    a   ac   a   b  a   (R , 2018). 
CCM a  c      c  - a  c   
 a  c    c     a '   a  a  
(R b , 2016). M a  a  a , , a   a  a  a a   
b , a   c    a . T  a a  ca  c   ca , c  
a  ab  a a  (CSAM), a  c , c   a c c , a   a  
 a  a  ac ,  a a a, a  a  acc  (Ca a , 2019; R , 
2018). Ma a , c  a  c  a  ,  b   a , ,  
c c    c  " " a a     c    '   
b ca   b    CCM  a  ac . (R b , 2018). R b  
(2018) a   c  a  c  " a  c  c  ( . ., c a  
c a  c c ; c  c  a  a ca   a a  c ; c   
b   a  a )" a  c a   a CCM . A  ,  a   
c a   a  b  a  ca    a   c , c  a   a   b   
acc a c    c  c    a '  , a      
c  (R b , 2018; R , 2018). R      c a  a  








 a , ba   a  c  (R b , 2016). A     a   
  a   a a  a a  acc   a  a  a c ,  
 a    acc ac  a  c c  c  (R b , 2018). 
D    ca c  a    , a  a  a  c a    
 c a  a a c , , a  PTSD, acc    a  
R b  (2018) a  N  (2020). O  c a  a , Fac b , c   a $52 
 a    11,000   c   a  c    
a     a a  a  a  c   a    a a   
. R  a  a     a c c a  - a a c   
(PTSD)     (N , 2020). F   a , R b  (2018), N  (2020), a  
Pa  (2019) ca   ac  a     a  a  b   
a . N  b   a  c  a '  a  c  a   
c  a  a  b  c c   a . 
W     c  a  a  a      
a c  ,       a  b  c  a  c  
a  a  (B  & C a , 2014), a     a  a  
a a  b     a   b a ca  (F   a ., 2014). S    
  a ,     ,  c    
" a, , ,  a , b   a  ac  a  a a  
a , a  b  a  , c  a  a  a  c a  c " (B  & 
C a , 2014, . 589), a   a  a  c   a  (F , A , & Wa , 
2014). T   ca   c    ac ca  a  c  c ca  








a  b  a  a  c  (R b , 2016; R b , 2018; N , 2019; Pa , 
2019). 
Statement of Purpose   
T  a a , c a a   a   a   c   a c  
a   a   c  a  c  ba    U  S a  a   
CCM a  b  acc  c a  a a. T  c  a  a  a   ba  
 a  c a   I a, B , a  Sc a  (2019), R b   a . 
(2015), J c   a . (2018), a  L   a . (2014). H ,  c  a  a  
 ab  a  b       '  a   
 a  c       c a . F  a a c ,  
c a   R b   a . (2015), J c   a . (2018), a  L   a . (2014) a  
a     c . 
C ea  Def ed C c  
I  a  a    a  c  c  a  a , R b   a . (2015) 
c    a    c ,  c   a   
. F , I a  a . (2019) a   a c     c   
c ca  c  b   ca  a  b ca  ac . R b   a . (2015) 
a  c c   Ca   a . a  G a   a . b  a    a c   
c  a   a  c ; ,   a  a  a . 
S a , J c   a . (2018) a  a a   a   c c  a   
c   a a  a  a  c  a  c .  S c    
 c    a c   c    a a  a   c   








T  c a '  a   a c   b  a  c ca  
c  a   a  c c . P c ca  c  c a   a '   
 c   a  a  a  c  a a  CCM   a  a  
ac  (F c  & Sa a , 2012). I  , c ca  c    c a    
 a  a  a  a   c ;  c   C -Da  R c  
Sca  a   P a  Q a   L  Sca  (H a -S a , 2010; C  & Da , 
2003). 
Def e he The e ca  F a e  
Acc   L   a . (2014), a  a  ac  c c a   b   
b a  a ac    c  a    c - c c  a  ab  
ca  a , c  a    C'   c ,  c  , a  La a ' 
 . F   a ,  c a  c  a  a a    c  
 c     cc a a  a  a  a   a  a a , c   a 
ca    (Ba   a ., 1996). F , a   c  
a c ca  b a a  a  (DBT) c    c  a  ca  b  
a   ac       a a . DBT  a  a   
 c a  a  a '  c   c ca   ac  a  a  
 a  a a . T   a     
"   a   -   ac   -  a ,  
- c  c   c - c  c ,   a  c   a  
 a  a  c   a  ( c a   a  a    c a  
a   c   ), a     a ca   b -  








DBT   ac a     c c , a a  c c , a  c   c a  
a . T       a        
 ac  a     a '  ab     a  c   
 a  (G  & C , 2011). 
P g a  I e e a  
 R b   a . (2015)  a    c  a   a   
c  10  11-  a  . H ,  c a  ,   a a  
b     a   a a . J   a . (2013) c c  a 30-  
a  a   ca  ; , a      
S   a . (2011)  a  a  90-    c a . T   
  b   a  a c  a  a a      a 
c a  ab   a ca     a c a . T  c   ac  
a    a   a  a   '  . A   c  
  ac     , a  a   a   a   a  a  
 b  -    a   . 
T   b c a  c  cc   a  a    a  a  
a , c  a  G a   a . (2009), J   a . (2013), a  S   a . (2011); , 
 c      c    a  ca . R b   a . 
(2015) a   c   a  a  a  c a    a  
  c  c c   a   b a a . T  c a '  a   
  ac  c   b   a a  ca     
c   ,  c a  ca   a  c , a a ab  a  








W   c   , a ca   a    ca  ca  b  
c   a    a a c  a  (EAP)  ac a  b  a  ac  
EAP c . B   a   a    S a a   a . (2013)    a  
c ,   ca  c  b  . T  a  c   a  b  
a  a bac    a  ac  EAP c ; , ac  a  a  a  
a  a    c  a  a    a , a , a  
-     -  c   c a c a   " 
( a a . 1). 
M a  a  c  b  b    ca    a  a . F , 
c c a  a     c a  c , a   c a    
ac    b a c c a   a c   . S c , a  
c ab a   a a  a   H a  R c  a      a  
ca  . D a bac    '   ca ac    c a  
ac ,  a a   -a a     c    a a  a c  
ac  a , a  a  c  a    a   a  a   
 ( S a a   a ., 2013). 
T  c  c a    c    a    a a  
a a   a    b a    c a   a a    
. R b   a . '  (2015) a-a a   c c  a   a  
c a c    a    b . W    a a   
    a c a , acc ab   , a   a ac      








c  b   a  c  a a  b   c  c a  a    a  
a   a a     a  . 
 Rationale of the Stud   
T          a  a  ab   b   
 a  a  a    c  a  a   a  
a  b  a  a   a  a      c a  a  c  c  
a   CCM a . T  a ,  c a  a   c  a    ac  
a   a   c  b  a a  c a   a  (R. 
L -G a a, a  c ca , Ma  15, 2020). I a , CCM  ca  b   
  a c a   b  c   a a    b a c a . 
T      a    a  a   c   a c  a  
a    c  a  a  a  a    a  a   
ab  c   c  a  (J c   a ., 2018; L   a ., 2014; R b  
 a ., 2015). 
P , CCM a     c a  c    a    a  
   a   a c a  c  (AI), c  ac   a  a  c a    
c a  a a c  a  - a a c   (N , 2020; R b , 2018; 
R , 2018; G   a ., 2011). R b  (2018)  a  c a  a   
 b    a  ca  a   a    CCM a , c   
 c  a  ca     c a   c  a a   
. T  c  c  ac  b        a  
a  c a  a      a  a  a ,  c a  








2018). E c    c     a   a   c a  ca  
 a   c a   c  a  a     c a  
a  c     a  (N , 2019; Ba , 2020). T   b   
c a    c  a  a   a    (N , 2019)  
 a  c a   ab  c  a  a   ca   a  b   
, a ,   (L   a ., 2014; R b   a ., 2015). T    c  
a   a  ac a  a  c  a  a a ,   c a   
c c  a a  a a    c . 
Conceptual Framework & Model 
T  a   c   a   c  a  c  c  
a ,  a c  c   W c  R c  M     a a    
cac . T  WRM a     b c c a    a  c  a  
a  c c a  c  c c a  ac : , - cac , & c   
c  b ca  ab  a  a     a  a  
c ca  c . T    a c a  a  a  a '  c ca  c  
 a   ac     a ab  c , c ; b , 
c a  a , a ,   (R   a ., 2015). 
W f ce Re e ce M de  
R   a . (2015)   ac  c   b ca   a   
ca    c ca  c   c  a   ac  
. T  a  ca  a    a -  c  a   
a  c ca  c  a  a c a  c ca  a ab  b  c a  a 








a  a   a  c c a  c  c c a  ac  a  c  , 
- cac , a  c   c  b ca  ab . T  a  a   
a    c c  a    a   c ca  c  (R   a ., 2015). 
A  a '    c ca  c   "a a  a     
 c a  a ab  c  c  a  b , c a  a , a ,   
," acc   R   a . (2015) a   a    ac  . T  
  c   a   c  a  a a  a ab . N c   
  a  a  a    a  ac , a  
c a   c ca  c , a  a , a   ac  a c a   
c ca  c , a  ca  b   (R   a ., 2015). T  a   c  
a  a   CCM  b ca     ca   c  a  a   
  ac   a c c  a  a  b   c b     
a c a    a  a . 
Fac   a  b  c ca  c  c  , -
cac , a   c . M    '  c ca  a a . 
I a    ab   c ca  a  a  c   a   cc  a   
  ac     a  b c  a  . C ,  
    a        a    
. S - cac  a  c    a  b   ca  a   
a a   c  a  a   a . I a    - cac   a  
  c  a a a , a  c , c  a  a a c   b a c  . A a , 








a   " c a  , b - , a     c - a a a " (R   
a ., 2015). 
T  a  c     c   c ca  a    c   
 ac  b  ac  a  c a  c ca  c  a   a  c   
c . R   a . (2015)  a  "   , , a , 
b , a  c a  a " a  c . F ,  a  c     
 C  Da  R c  Sca  (CD-RISC)  a  c      a  
c  c c . T  a   a   a  b  
c ca  a  a  c ,  c   c a  b  
c ca  c a  a  , - cac , a  c  (R   a ., 2015). 
Research Questions 
(1) C   a  a  , a   c   c , b , c a  
a a c  (STSS), a  c a  a   b  CCM   
 c  a  a      a ? 
(2) C   a  a  ,  c  c  a  -b -- c a  
a ac ,  b , a   STS-- c  c a    a c a   
 c    c  c a    a c a  a  
a ?  
 Limitations 
T  a c  a     acc b    a c a ' ac  a  c   
a c  a   a   a  b  ca   c . T ,  
c c  a ca  a a ,  a ab   b  a  a  a   c . T  








c  a   c  a  -b     c a a . F , 
a a    a c  c   a  b   a     a  
 a a . T  a  a a  a     a  c a ,  a  
  a ab    c a  a a  CCM . La ,  c a  a  
  a   a  ac a    c  COVID-19 a  a . F   
a ,  a   c  a  a    c    a  
a   ac   ac  ac a .  
P a   a c  a ,  a     a    
a  ac  a c a     a  c  b , c a  a a c 
, a  c a  a ,    K a  (2009)    c  
   a a , a   c  a a,  c a  , a  
ca     ac . T  a c    a  acc    
a   ca   a     c a  a     a a  
    a . 
A a  ac   c a  c  a  b  A  a  S b   
2020. T  c a    ac  c   a  a a c  b   a ; 
,   b    a c   ac  a a  a c a   a  a  
  c a       a  a   a a    23%  a c a  
a  a   . S  1  a  a  a   7.12% b   a   A  
    J , a  S  2  a  a  a   2.91%. A  a   a a  
c   a c  ca   c  a c a  a   c  a  a  








F a ,   a    a c  ,  ca   
 a     c ca    b  ca  b ca  ab  a  
 c  a  a  a c ca  a  cc a  (R b , 2019). T  
  c   a   c    c  a . A a  
a  c  a  a ab  a  a  ac   c     
c  , c  a    b  c c c  (D , W a , & Caba , 
2019)   a   COVID-19. T  ca    c    a  a   
a  c   a   ac  a   c ca  c  a    
c   c     a . 
Definition of Terms 
B   a   a  a , a a , a  c  a  
acc  (Ma ac , 1982, . 3) a   c a ac  b  c c , c ca  , 
  a ac , a  a  c , a  b , a  
ca  b  (S a , C a , & W , 2007). 
C e c a  c e  de a  (CCM)  a  a     c  a  a  b  
c a  a     a   c  . 
C a  fa g e cc    a  a  c a  a    
a   -ca  (F , 1995). 
P ec e fac  a   a  c  a  , a a ,  a  a   
  a  a a  a    a a a a  c  (R , 1985, . 600). 
P ch g ca  d e    a  c ca  c c , c  a    
, a , a   (F a -J , 2014). 








a  a  a  c  a  a    a  a  c    
(F c  & Sa a , 2012, . 675; 2013, . 16). T   c a  a c   a  a  
c  c   c , a   c a    a    -
 ac . F   a , a a   c     c  
a   a   c  (F c  & Sa a , 2013). 
Sec da  e e  c b  a   a  ac   b   a a a c  a  
  a c  a a c a a  (B -Z , G , & S a , 2012, . 133). 
Re e ce fac    c  a  c  a    a  a  c   
c   b    a '     a  a  
(C a, K , H c , T c ,  Ka c , K b a , W a, & L b, 2018, . 79). T  
cc  b  a  c , , - cac , a  c  ( c a   










T  a   ca  a a   c ca  a   c  a ; 
, a c  a  a a   c    c a  a    
a  a  a  ca   a  b . P  a c  c c  c a  
a , c  a  I a a  a  Fac b , c  a ca   a  
b  c    a  a  a    c a     
     . S    a c a   , a ,  
- , a  b  a ac   a  -b  (B ac , P a, & 
Pa c, 2015; S c  & Wa a , 2019). T ,  a    a    
ac  a c a   a      a  a    a   a   
a  a  (O'R , 2018; K a , 2009) a  CCM a     -  
 a     a    (Pa , 2019). 
A  a  a     ac  a c a     
(K a , 2009; B ac   a ., 2015; S c  & Wa a , 2019),   a  a  
a  a  ca ac  a   a  a     a   c  
 a a . T  a ,  a   a  c  c a     a  
a  c  a  ( a  c c   Rac  L -G a a). C ,  
a  a   c   a   a   a   a   c  
a  b ca  a  a  a a  ac .  F ,  a   
 a    a   a  b  , -b , a  
b  c    a  (J   a ., 2017; Ma   a ., 2013). F a ,  








a  c   a a ,  a    ac  a c a   
c  a ,  c ca , c ca  c . D c  a a   c  c  
c  a   ac   c ,  a c a  a  a   ab  a  
a  a  c , c a   a  .  
E posure Risk & Stressors of CCM Protocol  
Acc   a ,  c   a  a     
a , c   ac . W     ,  b  a  c  
c a  b  ; ,  b       a   c ca  
    a a  c  c  (Za a  a ., 2010). W  c  
b  a , ba a c    a   a , a    a  c , 
   c   a  ca    c   c a     , 
a   a a  - a  . T  c  a   a  b , 
c a  a , c a  a a c ,  ca  a a (Za a  a ., 2010; R  
& B c , 2014). W     a  c  ba    , a  a  
  c   c a    a  a   c    a   
 c - a    a '   (R  & B c , 2014). 
 Ad e e Effec  f P ged V e g 
 I a    a    a c a     c  
a   a  a  a     c a  a   c a  a a c 
    a   a  b a   a ' ' a a (Ba  & K a , 
2006; R  & B c , 2014). I a    a a , a   c  
a a,  c a  , a a  a a   a , a  ca   








2009). S c - a   a  a   CCM a  c    a    
b c    ac  a   (R b , 2018). N   a  c   
  a   c  a  c   a  c , a   ,  a  
. 
W  CCM a  a      a c c a  PTSD,  a    
     c  a  ca  a a a , c a  a a c 
, c a  - a a c  , a  c a  a  a c a   
c a     ac  (B -Z   a ., 2012). N  (2020) a  R b  
(2018)        CCM a     
  a  a    , a a c    a c a    c , 
c a  ca  a a , a , c a  a , a  a  b  
a b    a c c  -  (B -Z , G   a ., 2012; C a   a ., 
2014). I   a , a   ca  a   a a a  a  a  b a a  
c a    (K a , 2009), a   a   a    c a  
a a c  a  c a  a    c  a  a . 
K a  (2009) a   b a c a  a  a  c   a   
 b c   b  a  a     c  a  a  c  
a  a . T  c a  c  c    a   
 ,     c  a   a   ca . T  c  
acc     a      ac     a  
  c  a     a  a c c  (K a , 2009). S a , CCM a  
b c b    a    c      a    








a  "  a   c a  ca c    , a  a a  c b  
 a  " c ," " ," a  " c " ( . 13). C , b     
,  a a  a    a   c   a     
a a     c a  c b - a ca  (K a , 2009; Pa , 2019). 
O  , c a   ca   a  a '   a  a    
c  a     a  a  ac   . F c , a , , , 
a  c  c    a  c   ,  c  a  a  a 
c c a         b  (K a , 2009). T  ac  ac  
b  c  c  a  CCM a  a  a  c a     ac  a  c c 
 a  a     a a a , a , a  a   
(K a , 2009; N , 2019). 
C  a c b ca  a   c  a  a  a   
a c   PTSD  CCM a   a     . H , 
  c c   a  a  b a  a   a a   (Ba , 2020; 
N , 2019),   c    a ca  , a  a  c  a , 
a  a  c   a  (C , 2014). B  c a ,  a a , 3.6%   
  a  a   c  a a c  ( . ., a a , a  a a, 
c ba , c.)    PTSD c a acc    W  H a  O a a  (2013). 
I  & Bac  (2017)       WHO  (2013)  
   a  c . W  c c   a a  a    
a  b  - a a c   (PTSS), - a a c , a  
ac  c a     I ac   E  Sca -R  b ca  ( , 








c   a ac    c a   PTSD,  40%  -
a a c . O   I  b ca   a ca   c   -
a a c . T  a       a a   ,   
    , a  ,   (I  & Bac , 2017). T  
a  c a   b     a   a  a   a  ca  c  
c   c  ca    a a; ,  a     
, - a     . T ,    a  
 a  a  b  a  c a  a a c  a    PTSD. 
S c a  Med a U e 
 CCM a     -  a  a   a    (Pa , 2019), 
a   a a    a  a    a   b  a a  
(O'R   a ., 2018). W   c c  c a  a,  a  a  c    
a c  a , a a  a a  a  c  c  a    c a  
a  c     a  a  (O'R   a ., 2018). W  O'R   
a . '  (2018) ca    54 a c  a  11-18,  a c a    
a  a      a a   -b  a  a a a   
 a c  c    . T  a    a  b  a   
c a   ,  - , , c a , a  a c . A c  
 ac    c  a c    b  a c a   a  a  
c a  c  a  a  (O'R   a ., 2018). 
T ,     a  b ca  c a  a a  a  a   
c  a  a ca   a  a  a  a ,  c  c  








Wa a  (2019)   a   c a  b  a a     
I a a  a    (  = 0.49,  < .001), a  a , (  = 0.42,  < .001), c a  
c a  a  (  = 0.42,  < .001), ca  a a a c  a  (  = 0.47,  < .001), a  
b  a  ba c  (  = 0.33,  < .001). F ,  a  a a  c a   
b  a  a  I a a   (  = 0.36,  < .001) a  c a  c a  (  = 0.21,  < .019), 
ca  a     a  a   c   a  a  a  c   
c  a  (S c  & Wa a , 2019). T  a  a       
B ac   a . (2015)    a  b  Fac b   a  -b . T  
     a  a  b  Fac b  c  a   
(  = 0.45,  < 0.001),   a  b  a    a   (  = 
0.08,  = 0.08). T  ca  a  c   c a       
 (B ac   a ., 2015).  
W     a a  c a  a a  c a     a  
a  c c    a ab  c a  c a ,   ca  c a  a 
  -b   a c , acc   R c  a  T  (2014). T  
a  c a c  b        c   a  b   
ac  a   a      a a  (B a   a ., 2018). T  
c   ac    a a  a  a  c  c - a   c a  
a a    . C    a c   (B a   a ., 2018), 
 a     a   a a    ac  a     c  a . 
Lifespan Perspective of CCM   
Acc    a  a    a ,   a  a  








 a a        , a c  c  a   a   ab  
c   a  c  (N , 2020; R b , 2018; Pa , 2019). S  a   
b a  a a  a  a  a  a  a a  .  
B a  De e e  a d E  Reg a  
 S  a  b a  a a   a   c   a    b a , 
c ca   c '  a  a  c , c   a   
a  a . "N c ca    a   a  b  a  a   c  
c  a   b , a  a , a , a  a a " (S   a ., 
1999, . 860), a     c  c  a   a . C , 
a a , a , a  cc a  b  a   a a a  c a   a c c   
a  (S   a ., 1999). 
U a   c   b a  a a   a  c    c  
a  ac  c c  ac   a a    a , a    a a  a  
b    a  a  a a  c . H ,  a  ac   a   
a   a  a  (S   a ., 1999). I   a   a   c   b a  
  CCM a , c  a  a    a  a    a , 
   b a   c   a  a  a  a a  ,  ac   
 ab   c  c    a  a   a  ac    c . 
Age f he W e  
Acc   J   a . (2017),  a   c a     a  a  
      a  , ab , a  a c  c    
 acc    c  . C ,   a , a   a , 








a  a   a  a  c    . F ,  a  c   
a  a  c c  a    c a . T   a  b a  a   
c ca  a  a  a  a c a   c a  -b  a  c  b  (J   
a ., 2017; Ma   a ., 2013). 
Ma   a . (2013) c  c ca  a    a   a  
 a  b  a   a '  ac     a   b  a ; 
,    c a  . Ma   a . (2013) c   c a  
c   b  Ca   a . (1999) a  a    a  c   
a ab   ,    c c  ab   , a    
  a  . F , ba   R a '  (1989) c ca  
c ac  ,      a      a ac  
  ,   c a    a ac  a   
c a    c a , a   a  b . 
Ma   a . (2013) c   c c  a   3,701 , aca c , a  c  
  a a   a  a  b  ,  c ca , b c , 
a , a  - a  c c  b  a a  c a a c  (ANCOVA). Pa c a   
 a  18 34, 35 44, 45 54, 55 68,  a a  a   43, a  a   c   J b 
S c  a ,  QPS N c Q a   a  a , a  T  
M a  M a    W -Fa  C c  ca   a  ba a c  b  
a  a   a  ca  a   a c   c a    ac . F ,  
a   a  a c ca   a a   " a   a  c   b 
 a  a   - b  ( b a   a ac , , a  - a  c )" 








R      a  a   a  c   - a  c c   
 a ac  a  a ; ,    aca c ,  a  
   c  c , a    b a ac . T   a  ca  a , 
a  a c a  a ,    c a  a  a  a  - a  
ba a c ,  a c a    a    . T    
a ca  ca  c  b   a    , ca  a  a  
a   a  -b    a  c a   a   a ac  (Ma  
 a ., 2013). 
T   a   a  a   a   b a   a  a  
a    c    a   a  c c  b   a   
 a  -b     c  a  a   c   . 
Y  a    CCM a  a   a  a   a    
c a  a  a     a  c . W   c  a  c c  
a   a ,  c   ca  a    a  c   c   
c  a  -b  (c a  a ac , b , a  STS).  
Ps chological Resilience in the Workplace 
W    a    CCM a   a   a c a   a a 
 - a  , -  a ac   a  a   b c a   c  
 ac     a a c a a . A  a  , R b  (2018) a   
c   ca   CCM a ;  a   c   b    a  
a . T  DSM-5   a c   c ca  a  a  a  a  a  
  c a       acc   a a  ca  (A ca  








Ba  (2020)  a c  a c  a   a   ca  b  B  
P c  O c  C a  (BPO),  a  c  c ac  ac a  a  
  CCM   a  c   a a ca  . T   
a "  c   b a  c , a, a  a   a   
a ca      ca ab   c   c  (Ba , 2020). S c  
a a    ca    ' a  a  c a  a  a  
ac  a a   (N , 2020). A  a    a , c a  a   
 a a   BPO ,   a a c  24-  a a ,  b a   
a    c  a  , a a  ac    ac a   c  , a  
 a  a  c a   "  a ." E     a   
, c  c a   a   a   c a  c a  a    
 a a   a  CCM a  (Ba , 2020),     a    
a  ac   c . 
T  a ca   a  a     ac    a  c c . T  W  
H a  O a a  (WHO)     1948 a  a   a c   
ca , a , c a  a , a   b   ab c   a  (W  H a  
O a a , 1948). S c ,  a  b  a a    a ac , c a  
 c  a  a '  a ,     a  c a  
 . I   a   ca ,  a ac    a  a  
 a   a    ac   a , a a    a a  
c   c   (M  & S , 2004). 
R c  a  a  ca  a     c  c c a , 








a ab  c c  (M  & S , 2004). A c c   a   b  
aca c a   , c  "a  b   a c   c  a  
a  a  a a     a   b c a  a  , a c a   a   
c   -  -b   " (J c   a ., 2018, . 33). F   a , a 
a   a   a  a  a   b  a  a  c c a ; a   
a  a   a   a   c a    ca ; a    
 a  a    (L   a ., 2014).  
T a  Ve  P ce  The e  f Re e ce 
 R c    a  "a  c   cc  a a a   a " ( .1); 
,    a      c  a  a ab  a   a c  
(Ga -H a a   a ., 2020). A    a  cc    c  a  
c   a ab  a ,  a  a    b   b ca  a b   a a  
a ,  a c ,   a  a  a  a  '  a  c  (Ga -
H a a   a ., 2020). T  a  '    c ,  c   a  
, c   a  a  b c  a  c  c .  
S  , c  a   W c  R c  M ,    a  c  
 a  ac   b  a  a  c , c  a   a  c  a    
c   a  c  (R   a ., 2015). S a , L   a . (2014)   c  
 , ,  c  c c   a - , a ab , a  
c c - a  a   a  a '    c  a   . T  a  
    289  b    a  b  a , 
c , c , a , a   a  a  a c    NEO-FFI, C -








N a  A c  Sc   a c a a  . T     a ca   
c a  b  c  a  a . A a , c  a    a  a  
 a   c ca  c  a  ; , c  a  
 ac  b  c  a  a  a c  (L   a ., 2014).  
R  a     c   a  a  a   ab   
CCM a   a  a  ac c  a  c    a a   a  a    
   (L   a ., 2014). T  a c  ca  a  a  a   
c a  ba      c   c  a   a  c a  
a  b   a c  a '  a  c . 
C , Za a  a . (2010) c  a  c   a  c  a  
a . T  a  a   c ca  c    a c b  c a   
 -  ac  a  c   c a . T  a  a   a  
a   c ca  c   c   c  a  ac  a  
c a   a a a  c     a   (Za a  a ., 2010). 
R a c  a   c  a  a c  c   c   a  a  
a '    c  a  c   '  " , b , a   
ca ac " ( . 5), a    c  c  acc b  (Za a  a ., 2010), a  a  
 a a a    a , c , a  -  b a  (I a  a ., 2019). 
T , c ca  c   a c  c    a a c  a c c c   
c   ca  b     ac , a  acc  b   a  
a  a   a  c c  (I a  a ., 2019; T   a ., 2012). 
H a a   a . (2020) c c  a    c    c c a  








  a  a  ab  a  ( . ., ca c  a , HIV- c  a , a  
a   c   ca c ) a  a   a  b  c  a  
c .  R    c  b   a  a  a   ab  
a  a    a   c . W  c a   c    
c  ,   a  a   -  c  a , ,  
  c    b - ,  , a   a a c  a  
 - c   (H a a   a ., 2020).  
R  ca  a , a     a    , b   c  
 a    a    c  c   ab . G  
a   b   c  a  ,     a  a  
  a   a   ab  a  a  a    
(H a a   a ., 2020). F ,   a  a   a  a    a  
 , a   c c    a   a c c   a .  
Protective & Risk Factors for Resilience 
P ec e Fac  
 W  a   c  , R   a . (2015)  - cac  a  c  
a  a  c c a  ac  a   c ca  c  a  a . 
E    - cac     a  , c a   a ac , 
a   c   (R   a ., 2015). H a a   a . (2020)    
a c   c  a , a   ac  a  a c c a  a   c ca  c . F  
 a , a c   c  a  a  c    , c a  c c ,  
a a , , a  acc a c  a  c , a   a  a   








A a ,  a  a  ac   c ca  c ,  a c a   
 a   ; , c     c    c c  (Za a  
a ., 2010). Za a  a . (2010) a , "W   c   c c  a  a    
, a  Ea   a   a a  a  acc a c   
c ,  a ,  a  a   a      " ( . 8). 
F ,  a  a a  a  a  c      ba c 
a  b    c . T     a  a a    a  a  
a      a  c    (Za a  a ., 2010).  
M   a . '  (2013) a c  c  a   c  ac   a a   125 
a  a    a  a . R    "   "  (PIL) 
c  a  a c a    a      a  a a   
ca      a     . Pa c a      
c    c   a  a    , ca  a ac   
ca ab   c  " a  "   c  (M   a ., 2013). I  a  
Bac  (2017)   a  a     c  a    
, a a ca    a  . A   a   -
a a c  (PSS)   c a  a ,   a  
a ac   a  a  a  a  ac  a c a    a a c . T  a  a b  
      '   a     c a ,  
a  - a a c  (PTG) a c a      a a 
c  (I  & Bac , 2017). 
F , I  a  Bac '  (2017) a c  a   a c   c a  








T    a  80%   375 c  a  a  a   c  c a   
  2011  a ac   N a . A  c c  a  a a , b ca  
  S c a  S  Sca   a  c a   c  c a     
 - a a c   a  b   I ac   E  Sca -R ; , 
 a  a   a   c  b . T   ca  a   a   
   a  a   a  (I  & Bac , 2017).  
L   a . (2018) c  c c    c a   a  ,   
  c a    c a   a a  b a      220 
c  . T  a   a ca  a a  a   c , - cac , 
a  c a      a  b -   c a  a   
 c , - cac , c a   , , a  b - . T   
 a    ca    c    a  c a  b - , a  
    (L   a ., 2018). 
F a , ,    c  ac  a c a   c ca  
c ,   a   a   a - a a  a  a   a a   
'  c  a  a  a  c . I   a c a       
a  a   c ca  a  -c ca  a , c  a a   a a   
PTSD a  c  , a  a  a  a   b c  -b  (Ba a  
& Pa , 2016; J c , 2018a). M   a c ca  a   a    
ca ac    a a   a   c  a  a   a  a c  a  
ca  b  c  a  c a   a . P  a c  ab  a    








a  c   c    a   a  (Ba a  & Pa , 2016). T  
c c  ca   a cab      c c a  c  a . 
T    " a    c    ac      a ac  
a  a c  a  c   b c  -b " ( . 65), Ba a  a  Pa  (2016) c c  a  
 227 a a     a a   T  M  A  A a  
Sca  (MAAS), Sa ac   L  Sca  (SWLS), C Da  R c  Sca  (CD-
RISC), a   P  a  N a  A c  Sca  (PANAS). R   a  
c a  b   a   a ac  a   a c . R c  ca  
a  , a   a ac ,  a c , a   a  a c . T  
ca  a  a a  a  acc a c  a   a  c ,  a  c   c a  
-b  (Ba a  & Pa , 2016). 
W  a    c  a , J c   a . '  (2018b) a-
a a   a   a  c -b a a  a  (CBT) ba  a  a  
a  c    c  a  a  -b  a  a c  c . O   
  a  / a ,   a   a  a  c  c c  
(C   a ., 2014; L   a ., 2011; S a   a ., 2015; McG a   a ., 2014). O  
 a     a ,  a  c  c  ca   (M a   
a ., 2014; S   a ., 2014; C a   a ., 2015; E   a ., 2014). S     
c  a  c ca  ca   c  c , , c  - a  
 a   (J c   a ., 2018a) a  CCM a  c  c - a  .  
A a     c  B '  (2010) READY (R c  a  
Ac   E a ) a  a  c  c     a   








b  a "  16 a c a  ( . 269). T  a  c c  c   
c  a  c c a  -b    a  a    a  b  
 a  a  a ac , a   a     - a  
 a  . T  a '   c  ac  c   , 
b - , a   . Acc a c  a  c  a  (ACT) a  c -
b a a  a  (CBT)  ac c  a ca , a      
J c   a . (2018b).  
B '  (2010) - b c    ca  c  a   .05   
a  ( c  a  c     a  a  ac ),  c   
    a ac  ca c . F   a ac  a  ca , 
 a   a    c , c , a  a ; ,  56% 
a   a   a  c , a  31%  a    c a  a  
(B , 2010). T     a   a  a   .  
F a , A   a . (2013) c   c   c a    
a  c  c  a a     . T  a   a a   
b  c   -ba  a  CBT    c a  a  
 c , a c  c , a    a  ac  c  c   
 a . P a   a  a  c  a    a  a  a  
    a a c  a   a  a , c a     
, a , a  PTSD (J c   a ., 2018a).  
T  a    a '  c  b      90-  
: " a a  a ,    a   ac a  a a    a  








c  c . Pa c a   c  c ca a   a  a  a   
 a   ac   a  a  a c , a -ba  , a  ac c   
a a  c  a . I  a , c   a  c  a   a   
  a   c    , a ac c    c a  c  
c   ac   a   a  (A   a ., 2013).  
A   a  a      c  a  a  ; b  
a , c   a , a  18  ac   c . A - a , a -
a  ANOVA  ca   c        G a  
H a  Q a  (GHQ), ca   c  a     a  b  
 -  a  18    (A   a ., 2013). R   a   
a  c  a  ca  a  ab  a    a a c .  
S a  a  D b  (2008)   c   c  a    c , 
, c  a c   c  a  c  ac  b  c c  a a a  
  57 c   b  c a    a   2-  c  
 a  (  = 30) c a      c  a   (  = 27)  
c a  . T   a   c  a a a  c  a , a , a  
c a c a  a  b   a  -  a . S a  a  
D b '  (2008)   a   b  ac   a    a   
c c  a . T    c ca a  a  c  c  a   
c  b a a  a , a a  a , a  a  a   a . 
R   ca  c a  c    D a  R c  Sca  (DRS) 
a   C Da  R c  Sca  (CD RISC) a   c  . W  c a  








ca , a       a    b -  c  
 ca    a   c   -c  a  a a -c  
a . F a ,    a   c  ca     
, a  a c , a  c   ba   c    PANAS, C   
E c S  D  I  (CESD), P c  S  Sca  (PSS), a   
S  C c  (S a  & D b , 2008). R  ca  a   ac a  
b  a a  a  c  a  ca   c  ca ab   -  a  
. 
R  Fac  f  Re e ce 
 A a  a   c    a c  a  c   a  c ca  c  
 c  PTSD, ,  a   a  a a c  ,   c   
a , c a   , a , c a c , b a c  ab , a  
a c a  b a  (M   a ., 2013). C  a  ca  a   ab  b ca   
ca   c  - a  c  a  a  a  a ;  
ab   c   a    . T  ca  a     ac  a  a  
 ac  a   ac   ca   a    (Za a  a ., 2010). 
M   a .  (2013)  a   ac  ba   a   c  
a a  a   a a   a -c  c c  ac c  ca  (PCCTS) a   
 c c  (LEC)  a  a  b  a c a   , a  
, a a , , a  b a c a c . I a   c a ac  b  
 a  , ,   c  ba   c    C  Da  
R c  Sca  (CD RISC). F  a  c   B c    








 c c  90-  (SCL-90-R), a   a c    ca   
(AUDIT). 
B  c c  a - a  a a   a a c  (ANOVA)  c a    a  
a  c  a a , ca  c  b  a  a , c  
c , a    c  a  a a  ac  a     
c . Y  a c a   c a    c  a     
c a  a c a    - c   (P = 0.012 a  P = 0.048). Y  
a c a  a    a   c a  a a     a  c  
ca      a  a  a a  ac . F , a  a  a  
c a    c . T   ac  a    a  a '  ab   
 c   a   b  c    a  a  a  
      a a , c  ab , a  a  a  (M   a ., 
2013).  
Online Resilience Programs 
 Ba    ca   a c a  a    c a '  a   a  
a a  a c   24%  a   a   c    a     
    COVID-19 ,  a  a   a   a  a   
a   ac a   a   a   . A a-a a   21 b-
ba  c ca   a   2000  2016 c c  b  Ca a   a . 
(2017)  c a  a   a  a  a c   a    
 a   a  a c  a  45%. 
E    a a c  a    c   , " cc a a  a  








c ca  -b  ( =0.37, 95% CI 0.23 -0.50) a   c  ( =0.25, 95% CI 
0.09 -0.41) c a    c  c " (Ca a   a ., 2017, a a . 3). W  
c a   c  b  ca  a ac ,   -  ac a , 
 c c ac  a   a  ac  a ,  a ca  
ca  c   . R     ca  a  a ,  ac a  
a  c a   -b   a  a  a   c c    
c , , a  c ca   (Ca a   a ., 2017). A  c ,  
 c  a  a    c  a  a  c c  a  PTSD,  
a    c  a c . F ,   c ca , c  a  
c c   -c , a  a a ab      , a  
a   a  -b  (Ca a   a ., 2017). 
O  c  c c  a  a  c   R c O  (ROL) 
a  (Abb   a ., 2009) a   R c @W  (RAW) M  P a  (J c   
a ., 2018b). T  -ba  R c O  (ROL) a  a  a   c  
 a  c   c   c :  a ,  c , 
, ca a  a a , a , - cac , a  ac  . T  a  a  
a   a c a   a   a   - c   ac a  b  a 
c ,  acc    a  . Fac a  c   V a  Pa  a  
a     a  (Abb   a ., 2009). T      
c   a    a  a      
( :// . c .c / a - - /),    a c  








A  c c  b  Abb   a . (2009) a   R c O  (ROL) a  
 a  a a a  ac  a  a a   c  b   a   a   
a a , a  a   a ca   27    a  a a  c a   
26  a c  . T   c c  a a  c  a   b  
a a  c   c    A c Ha  I  (AHI), T  W  H a  
O a a  Q a   L   BREF (WHOQOL-BREF), a   D  A  a  
S  Sca  (DASS- 21)   a a   a  - , -
, a  -  (10      ) 
T   c c   ca  c  b   a   , 
a , , a   , a  a    DASS-21, WHOQOL-BREF, a  AHI, 
 c c  a  a  MANOVA . T   ca  c    
  c  a  a  c   b  ,   c a  a  a   
   -   . T   a    , c  a   
 b a , a   a    a     -   ac  46 
c , a   a  a    a  1  (Abb   a ., 2009). 
W    c  a    Abb   a . (2009), J c   a . (2018)  
 a   a  -ba  c  a  c  a a  a    
 b   " ac  c , a , a  a a " ( . 36). F ,  a  
a     a  a  a  a a    a a   a a   a 
-  a  b  c  a a   29 . T  a  c   a a   
' c  a  c ca     10-  C -Da  R c  
Sca  (CD-RISC 10),  Acc a c  a  Ac  Q a -II, a  a c a   a  








F  c  a  a        a-
a a  (J c   a ., 2018b); acc ,  a    R c @W  (RAW) 
M  P a . T  a  c   20-25-  c ca a  a  
 a     c -ba  a   c  ACT, M -
Ba  S  R c , a  C a -F c  T a . T  c '  a  c    
 ac c ; ,  a  ac   a  c  a a  c , 
 a , a    a c  c ca  b - a a , a    
c  (J c   a ., 2018a). 
O  11   29 (38%) c  a   ,  16 (55%) ac  a  a  a  
(M=3.6, SD= 2.2). A ,   ca , a    a  a ,    
c  ac   a  c  a . Sc    -   a  
c a  c    CD-RISC 10, c   c ca  b , a  
a a c   a , a  c  . Y ,     b  ca  
b  - a  - . R     c  a    
c   ac a  a . F ,    a  a ; a  
a  ,  c  , a   a      a    (J c   a ., 
2018a). 
A   a . (2014) c c  a   a   c   a  
M -Ba  S  R c  (MBSR) a    ac   90 a  
(44 a  a  46 c ). P  ab  a   30   c -  
a ,  a  a a    a c a   ac c  30-45 . T  a  
 a  MBSR a   acc a  ac  ac c   c  , c a  








a  c   -      7-  . T c  c  b a  
c , b  ca , a, ca  a , c    a  , , a a  
a ,  c ca , a   c  a a . 
Pa c a   a  a - a  -  c   F  Fac   
M  Q a , T  P c  S  Sca , C -Da  R c  Sca , 
S  V  Sca , a   L  S  Q . F  c   , a c a  
 a  c  a  a  50%   c a  a  a  c    a  - , 
  a   36   a  . T      a  
b  b c  c a  a  a  ; a c a  a  c   a   
ca  c   " c   a   a    c , , a  
 a  c a   c " ( . 8). F ,   c  75%-100%  
 a  a  a 30% a  c   a   c a  (A   a ., 2014). R  
ca  a  - ac     c  ca  a    c    
ac . 
T     a  c    a   c  a  
a  c  a a  c ,  a  a a ,  a   , a   
c a  . T  c  a    c     a  c   
c c  c  a . A a  c   b   a  c   
    a   c  b , - a ,  a c  
 -ca , a  a  c   -c c  a  c a   a .  
Resilienc  Program Measurements 
T  a-a a   c  a  a  c      








c  a  c  a   a   c , c  a   a  a . T  
a  a   R b   a . '  (2015) , c    c   a  
 c c  c a   c  a    c    a  a  a  b c  
-b . J c   a . (2018b)   c   c  , a  a  -b , 
c , a  a  a  a  a . T  a  a  a  a  
c  a c  a  a   -b   a   c a  c , a  c  a 
(J c   a ., 2018b). 
W   a . (2011)    a a  c c c    10-  
CD-RISC  a  c . T  a  c c  a a c ca    
ab  c  a    a  20 a   a a   c c  
. T  a   b   b  a  a  c a, " a    a  
 c c   a  a  a " ( . 2) a  c  c  a , 
a  c c , c  a , c c  a , c b , ,  
a  c  c , a  ab . A a   c a    a a    
a  c  a cab ,  a   a  a , a  " a c  a  ac c  
ca " ( . 4). O  -  a  a c   c  a  ba    
a  c   c . A   c a  b  , c , , 
c a , a a , a  ca  a ac . T  a   c c a   
,   c  c , a c , a , a   a , c    
a  a  a    a   (W   a ., 2011). 
F  a      , a   c     c a 
 a   a  a . T  a  c :  RSA, B  R c  








ac   a    c  a - R c  A  a  S  P , 
CYRM; R c  Sca ; READ-  ,   c a   a  c c , a   
a   a  a . W  a a  a  c c , a  a  a  acc ab  
C bac '  A a    ca ,  a  a  a  a a ab  a   
b ca . O   R c  Sca   a > 0.70 a  <0.95  a  b ca ,   
c  a   READ   acc ab  C bac '  A a   b ca . N    
a   c  a ,    B  R c  Sca   a  
c a   0.59   CD-RISC a  0.51   ER-89. C ,  a  
c    c c  a  c  c : ER-89, CD-RISC (b  25 a  10  
), RSA (37 a  33  ), B  R c  Sca , RS, P c ca  R c , 
 READ, a  E -R c  (W   a ., 2011). 
I  a    a , c b  a      15 a ;  a  
b  acc ab   c  ab . F a ,   CD-RISC c c  a  a  -
 a a  a  c  c a    ba  c ca     
  a a  . W  a   ab ,  a  
  a a  b   a ca  ca  c  b     
,    c a ca   c ca  a  c a   c . O a , 
c a  c   CD-RISC (10 a  25 ) a   RSA, a   c   
 a ; ,  c a  a  a  c c  a . F ,  a  
a    a  c  a   a a ab   c a  a  a   a  
 a  c c   c  a  a  c  . F a ,  a   
a ab  a   ca   c  acc b  a    a  a '  










T  c   a   a   c   a c  a    
c  a  a  ac a  b  a  a  c c a  b  a a  c  a   
c ca  c  a  a  a     ac . T  a   ba    
M   I a  W c  R c  (R   a ., 2015), a   a -ba  
c ac  a ac  "c a ac  b  a    c  a   c    
c ac , a a  a    b a a  c , a  a  ca " (R b   a ., 
2015, . 540). T  a '  a   c   LaM a   a . (2014) 
c a   c  acc    a   a , c a , a  a   
 ca . 
T  a c  c c  a c a  a a  c a , b      
S b . T   c a  a  c a  a a  c   a a a  a   
c ca  a  a a  a  b   c a . I a  a  -  
b   c a  b  b  a    a  a . Acc   a a a   
 Q a  1 (Ja a   Ma c ), Q a  2 (A   J ), a  Q a  3 (J  
 S b ). A   a   c     c c  a    
 a a   c    . T  a c  c   a    
c a   c   a  c a   b  c    a  a ab  
 COVID-19  c c   a  -   a a . 
H a c ca  a   a a  a  c c   c a  a a   
  a a   c a  c     c  a    








 F b a  a a   a ca     US  a b     
,  c a     . Ma  a  A  a a   c  a 
a   a   a   a   a  a c a  acc a . Ma  
a  A  a a   a a   c a  c   c  a ab   a 
c a  c a    a a c   a   b ca  a a   J . T  
c  a ab   a  c  a ab  c  c    P QOL a  10-  CD-
RISC. 
Participants 
S  a c a  c  497 c c a  c  a  a  18  67,  
a  " a a "  -  a   a   ca  b  a   c  a  
c  ba    U  S a . T a a    c a     
c ca  a   a    c a   a a      c  
. A   c a  a  a    c ca  c  a  -
b ,   c a  a  " a a "  c    a  c   ac  
  c  a . W   c  c a   a  a , ,  c   
 ,    a     c c b    a   
   a a     acc a   c   a   a . A  
a    a  a a    c a  b  Q a  2 a  Q a  3 
 c    . 
I  c c   ,  a c  a  ca  a a c c  a   b  
 c a , c  c    P a  Q a   L  Sca  (P QOL) a  10-  
C  Da  R c  Sca  (CD-RISC 10) a  a  a  a . F   








a , , ac , a    ca    a   a HIPPA c a  G  
F . C  a c a  a   a  a      
c   c ,   a   a c  .  
Assessments and Measures 
J c   a . (2018a) a  a  "A a  a   a  a  ,   
a c  a '  a  c ca  c   c  a" ( . 34); ,  c  
 a a  c  a    c   c  a  a  a   -b . P  
a  a  c  a  c  a  c , a  a , ca  a , 
c c a  c , a  -b --  c   , a , -- , 
 c    c   a  a     c  a  
a  a   / -b , c   c a  a ac , b , a  
c a  a a c . F   a , a  c   10-  C -Da  
R c  Sca    (CD-RISC 10) a   P a  Q a   L  Sca  (P QOL). 
W   a . (2011)   CD-RISC 10 a  a    c c a  
a   a  c c  a  c c  a   c ca  a  15 c  
a . 
C  Da d  Re e ce Sca e (CD-RISC) 
T  CD-RISC  a  c   a a  c c  a  c a   , 
  a   c a ac c  a  a   a  a  a a    
. T  CD-RISC a    a  c  a  a   a ab  
ac   a  a  c  (C  & Da , 2003). T  CD-RISC c  
25  a  c  0-100  a  c  ca  c a  c ,    








Ca b - S  a  S  (2009). F   ,  CD-RISC 10 a  a , c  
c      a  ca   a c  a   0-40. O  a 764 US a  
a , a a  c   31.8 (SD = 5.4) a     10-  ca  (Ca b - S  & 
S , 2009). T  a  a   a  c c  a  -  ab , a   
a    a   c a ab      a    (C  & 
Da , 2003). Acc   R , B , C ac , a  H  (2015),  ca     
  a   c ,  77 a   a a  c  a a ab  
(T a a    CD-RISC, . .). 
The P fe a  Q a  f L fe Sca e  
(P QOL) a  a    a  a  a  c    
    a   a a   c c a c . T  30-  
a  a  c c   c a  a ac /c a  a , b , a  
c a  a a c ; ,     a  a a c . W    
 200 b ca ,  P QOL a  b    a   c c  a ,  
a   a a  b ca    a   a   c a  
a , c a  a a c , a  ca  a a a  (G , La , M , 
& G , 2019). Acc    P QOL a a , T  C a  Fa  ca   c . 
T  - ca  c a   2% a  a a c  ( =-.23; c -  = 5%; =1187)  
S c a  T a a c S  (STS) a  5% a  a a c  ( =.-.14; c -  = 2%; =1187)  
B " ( .17). T  B  (BO) c  a  a 5% a a c    STS c ,  








Resilienc  Program Procedures  
D  a a  c a  b a ,    a -  a  
c  c   ac  a c a   c  ; - a , -a a , 
b :   ac   b a ,  c a , acc a c , - a / -
,  -ca , c , a a  , a c   a ,  
    a , a  : a  c  a  a a  c . C c  a   
  b a   c  a  (Ba a  & Pa , 2016; Za a  a ., 2010; I  & 
Bac , 2017; L   a ., 2018; F b   a ., 2006).  
A a  a  c c a  c   b a  a  b     
 a  - a  a a . T  a  ac a  b     R c  E a c  I a  
(REI), c  "  a c b a   Ra a  E  I a  (E   a ., 1997), C  I a  
(Pa , 2013), a  A -  a  (Pa  & P , 2006)" (Pa , . 49). T  c c a  
b a  b  a  S c a c a      a  a  c   
a  a    a a  a     a  c    a , 
b  a  a  . Acc   Pa  (2013),  c     
a   a a  a  , c   a CCM  a c a     
c a  c . 
O c   c   a ,    a  a a  -  
c ca a  a   "C a   M : T a a   B a ," c   
-ba  c c   -   / a a    b a , a   a  
a a  a  a   a   a  c c    a ca    , 








 a   a  a   a       b a   a  
c  a    , c  c , a  a  (B , 2019). 
F  b a  a , CCM     a  c   
  ac       . T  a  c   
c -b a a  a , a c c b a a  a , a  -ba  . 
T    c  45-  a  ac  ab  " c  a " 
ac a  b  a c  a  a  a    '  a . T  
a  ca  c    a     Tab  1. 
Table 1  
Mon hl  Programming Topics and Learning O comes 
  M           T c S  F c / L a  O c  
Ja a  S -R a  x E a  a - D c a  a  
, a   a a   
 
x D  a c  
x B -Ba  S  
x E  -EMDR 
F b a  S -A a  x E a  IQ- E a  c   
 a   
x G  V . F  M  
x M a  S  
x G  
Ma c  N b : S   
I ac   B a  
x M  a  I a  c  
x H  a a ac   b a  
x S  a   B a   
A  G  C a  x S c a  IQ- a     
x C ca  
x B a -    a  a a  
x S -E -   a   
Ma  Acc a c  x D a  a  acc a c  








x C a  
x W  
J  N -J / 
N -K  
x Ob  a  c b  
x Pa c a  
x F  
J  H  S  Ca  x S  R a  
x T   a  
x Ba a c  a  a  a  
x N  a  E c   
A  O c W  x S -C a  
x C a  Ha  
S b  A a  E  x L    
x CBT 
x D ca a  
Oc b  S a c   M a  x M a    
x M a   a  
x L   
N b  G  O   Y   
O  H a  
x L     
x M  
x M a  
x G  a  C a  
D c b  T : P a  
F c   
a  A a  C  
x M a  a  E a  T  
x Ac  c  
x S -c c  
x F b  a  c a  
No e: T c  a    a    Ja a   D c b   
E    a c a  ,    c ,  c  c a  
a      a    a c  a  a  a   
 a   . CCM  a  acc   c c a  24  a a ,  a  
a , a        b   a   a   c   








Statistical Anal sis  
S a ca  a a  c  a c ca   a a   a   a c  
 ba     a  a   a , a , a   a    
ac  (S   a ., 1999; J   a ., 2017). A  a    c a  a  
ca ca  c  a ab    a a . T  a     a  
a   c    c  a   c c a  . P  a c  a  
c c  a , a   a ,  c  a  a  ab  a    
c a  (K , 2004; S   a ., 2017), c  ca  a   a  ac  a  
  c    c c a  a , c    a  ac  
  -b . F   a , a     18-24, 25-30, 31-35, 36-40, 41-50, 
51+  c a , a     a   a   a . 
Re ea ch Q e  1 
T  a c       c a  c  a  c  
a  CCM  b  c a  c  a    c  a    
 acc b  b  a   c  a  -b . T ,   a c  
 a ; C   a  a  , a   c   c , b , 
c a  a a c  (STS), a  c a  a   b  CCM   
 c  a  a      a ? 
T  a c  c c  a c   a  c  b   , 
  c  a  a   ,  CCM  a   
 b   c a . T  c    c c   b   a  
acc    a  a   ba    c    c    c a ; 








c a  b    [F b a  2020]. T  a a  a ab  c    
c  a   [   a   acc ], a , a     
a c ca  a   . O c  a ab  c   c    
10-  C  Da  R c  Sca  a  -b --  c a  a a c  
c , c a  a , a  b --   P a  Q a   L  Sca . 
Re ea ch Q e  2 
W   c          a  c ,  
c a    a  ac a   -      c  
 b  a c  a  a  a . F ,   , c c   
 c  a , c  a   -ba   ,  a ,   a 
23%  a c a  a . M   Q a  3 [J  2020],  c  , 
   a  a  45-   -ba  a     
. F   a ,  a c  a a    a  c  c  c  
c    c  a  -b       a   a  
  a a c . T ,  c  a c   a : C   a  a  
,  c  c  a  -b -- c a  a ac ,  b , a   
STS-- c  c a    a c a    c    
c  c a    a c a  a  a ? 
H a c ca  a   a a  a  c c    ac  a    
a    c   a  ac  b   c   a a c  a  a  
a a c  c  ( a  . a a ) b  c a  Q a   [Ma ] a  Q a   








b   2020. D c   c    C -Da  R c  Sca  a   










D    ca c   a  a  cac   a   CCM 
a  a  c  a  ,  c   a a   c   a 
c  a   c   c  a  a  ac a  b  a  a  
c c a   a c a . T ,  a c  c c  a c a  a a ac   a  
 a c a  a   c c a  c  a   c   acc   
a  c  c a  c ca  c  a  -b  b  a a  c    
10-  C  Da  R c  Sca  a   P a  Q a   L  Sca ; a  
 c a    a  a a c  c     a  a   a  
 c  c  c a   c  a  -b .    
T , a c    a , C   a  a  , a   
c   c , b , c a  a a c  (STS), a  c a  a  
 b  CCM    c  a  a      
a ?   T  a    ,  a c   Q a  1 a a a  c  
c  a    b   c  a  a  c a  c    CD-
RISC 10 a   P QOL a a  b     c  a   a c ca  
 a a . 
R a c         a  a  a  
b   c   a a c  a  c  a  -b   a c a  
a a   a     ,  a  acc    a a c  b  
a a   a a c  a  a . T  a c   a , C   a  








c  c a    a c a    c    c  
c a    a c a  a  a ?  B     J , a  a a c  a  
a , a  c   a a c  a  a  ; 99.4% a  a  a    
, 17.1%    , 8.7% a    , 14.9% 
a  , a  1%   a  a  a . T  a   a c  , c  
 Q a  2   a  a ba  b   a a  a  c a   Q a  3  
c , STS, b , a  c a  a ac .  
P  a a   a   a  c c    a c  a   
 a  a a  0.05, a   0.80, a   c   (f 2 = 0.15)  Q a  1 a a, 
c    a  226. T  a  c  497 a a , a   
 a  c a . Da a c a  Q a   a     ab   
c  a a   361,    c   (f 2 = 0.15)    a  
(Fa   a ., 2013).  
S c   a a   ac   a  a   a   a c  
, a c c a ac c  a  a a  b  a   Tab  2, Tab  3, a  Tab  4; 
 b  c  a c    a  a  a a  a  (S  Tab  5),   
 a  a c   c  a c ca  a   a a   a  ac  
c  a c  .   
Description of the Sample  
T  a  c   Q a  1 (n = 497), Q a  2 (n = 417), a  Q a  3 (n = 
782) a a (  Tab  2). Q a  1 a    a  c   c   c  a  -
b  b  CCM a   a  a      c  a . Q a  2 








Q a  3. A  ac  a  ca  a     ab ,  a c       
ca  b  c   a ab    c  a a  a   c    a  
 b a   c a . 
T   a  a   19  69 a   ca  b   c a  ba  
 c c a  a . F  Q a  1,    b  a  ca   25-30 
a  18-24. F  ,  a    a   a  a . J   a    
a  c  W   Ca ca a  a , a    a  a c    
U  S a  C  B a , c   a , a   2019, W   Ca ca a  a  
acc   76.3%   U.S. a .  
Q a  2 a  3   a  ,  18-24 a  25-30 a -  a  
  50%   a , ca  a   a  a      
 c  a    c a  a   a  a  (S  Tab  2). I  Q a  3, 
62%    H a c  La ,  a  ab   18.5%    
U.S. a  (U  S a  C  B a , 2019), a  a b     
a ca  ca   b a   b a      c .  
Table 2 
Sample Demographics 
Va ab  Q1 Q2 Q3 
 n = 497 % n = 417 % n = 782 % 
A  Ca        
 18-24 128 25.75 78 18.71 146 18.67 
 25-30 166 33.40 168 40.29 353 45.14 
 31-35 64 12.88 73 17.51 122 15.60 
 36-40 58 11.67 40 9.59 68 8.70 








 51+ 27 5.43 21 5.04 26 3.32 
G        
 F a  285 57.34 233 55.88 427 54.60 
 Ma  212 42.66 184 44.12 355 45.40 
E c        
 W / Ca ca a  239 48.09 182 43.65 176 22.51 
 H a c  La  125 25.12 159 38.13 481 61.51 
 B ac    A ca  A ca  42 8.45 49 11.75 81 10.36 
 A a   38 7.65 9 2.16 6 0.77 
 Na  Ha a a    Pac c I a  3 0.60 3 0.72 5 0.64 
 A ca  I a   A a a  Na  3 0.60 1 0.24 3 0.38 
 N  A  47 9.46 14 3.36 30 3.83 
E ca        
 
H  c  
/ a  
( . ., GED) 
147 29.57 118 28.30 181 23.15 
 S  c  b    181 36.42 193 46.28 348 44.50 
 A c a  D  68 13.68 49 11.75 101 12.92 
 Bac  D  64 12.88 44 10.55 102 13.04 
 Ma  D  6 1.21 6 1.44 6 1.44 
 N  A  26 5.23 7 1.68 0 0.00 
No e. D    , c a  a   a  100%. 
I   ab   a  a  99%   a   a  a  a     
  a  b  Q a  3  a a  (S  Tab  3). C b ,    
a c  b  c  a ,  a   , acc    a  a   








      c  a c   c  ac  a  a . T  
ca  a   c    b  a a      acc   a .  
Table 3 
Freq enc  Table for Work Con e  
Va ab  Q1 Q2 Q3 
 n = 497 % n = 417 % n = 782 % 
T a        
 A a ab  286 57.55 417 100.00 782 100.00 
 U a a ab  211 42.45 0 0.00 0 0.00 
A a c        
 1  a  188 37.89 233 58.84 0 0.00 
 2  a  156 31.45 69 17.44 0 0.00 
 3  a  38 7.55 54 12.94 782 100.00 
 W  112 22.48 58 14.59 0 0.00 
 N  a  a  3 0.06 3 0.83 0 0.00 
P a  P c        
 O a   497 100.00 417 100.00 0 0.00 
 Ma a   0 0.00 0 0.00 782 100.00 
C        
 L  290 58.35 280 67.15 481 61.51 
 M a  126 25.35 71 17.03 152 19.44 
 H  81 16.30 66 15.83 149 19.05 
No e. D    , c a  a   a  100%. 
T   a    a  a c  Q a  1,  a a    
c   (n = 286) a  a   (n = 211). A L   a  c c   a   
a   a a c  b     a   c  a ab . N    








a ac , F(1, 491) = 0.33, p = .565; b , F(1, 491) = 1.14, p = .285; a  STS, F(1, 488) 
= 3.68, p = .056, ca   a    a  . F   a ,   
  a  a  a a . 
T  a   a    a  c a  b  Q a  2 (n = 417) a  3 
(n = 782). T  ab  c    a      ab    
       COVID 19 a c. T a a   ab   acc   
G     a   ca         a   
Q a  2,     c    Q a    a    
a a . T    a c    361 a a  a  c   a   
b  a   c a .  
A a  c    c    477 b c  a  c c  b    a 
L   b  c a   361 a a   c  b  a  a   
 477 a   ab   a . Sc    L   ca  a a c  a  a  
b  . A  c  a ab   - ca  ; c , F(1, 1197) = 2.77, 
p = .096; c a  a ac , F(1, 1197) = 2.11, p = .147; b , F(1, 1197) = 0.17, p 
= .680; a  STS, F(1, 1197) = 2.64, p = .104. M  a ,   a a    361 
b c  a  a a . S  Tab  4 a  Tab  5  c  a   b  a . 
Table 4 
Red ced Sample for Q ar er 2 and Q ar er 3 
Va ab  Q2 Q3 
 n = 417 % n = 782 % 
A  Ca      
 18-24 68 18.84 68 18.84 








 31-35 63 17.45 63 17.45 
 36-40 33 9.14 33 9.14 
 41-50 29 8.03 29 8.03 
 51+ 20 5.54 20 5.54 
G      
 F a  202 55.96 202 55.96 
 Ma  159 44.04 159 44.04 
E c      
 W / Ca ca a  168 46.54 168 46.54 
 H a c  La  127 35.18 127 35.18 
 B ac    A ca  A ca  45 12.47 45 12.47 
 A a   8 2.22 8 2.22 
 Na  Ha a a    Pac c I a  2 0.55 2 0.55 
 A ca  I a   A a a  Na  1 0.28 1 0.28 
 N  A  22 6.10 22 6.10 
E ca      
 H  c  / a  ( . ., GED) 102 28.25 102 28.25 
 S  c  b     174 48.20 174 48.20 
 A c a  D  42 11.63 42 11.63 
 Bac  D  37 10.25 37 11.63 
 Ma  D  6 1.67 6 1.67 
 N  A  102 28.25 102 28.25 












Red ced Sample for Q ar er 2 and Q ar er 3 
Va ab  Q1 Q2 
 n = 361 % n = 361 % 
A a c      
 1  a  196 54.29 0 0.00 
 2  a  67 18.56 0 0.00 
 3  a  52 14.40 361 100.00 
 W  44 12.19 0 0.00 
 N  a  a  2 0.55 0 0.00 
P a  P c      
 O a   361 100.00 0 0.00 
 Ma a   0 0.00 361 100.00 
C      
 L  234 64.82 234 64.82 
 M a  63 17.45 63 17.45 
 H  64 17.73 64 17.73 
No e. D    , c a  a   a  100%. 
Description of Outcome Variables 
10- e  C  Da d  Re e ce Sca e 
R c  a  a    10-  C  Da  R c  Sca  (CD-RISC 
10)  c  c  ca  a     40. Acc   Ca b -S  (2009), a  
a  a  c  a : 25  % = 29; 50  % = 32; 75  % = 36. T  c   
a  c  a     a  a  a  25  % = 30; 50  % = 34; 75  % = 38 
 Q a  1; a  25  % = 30; 50  % = 35; 75  % = 38  Q a  2 a  3. T a a  a  
c    CD-RISC-10   ab   a  a   a   a ,  









Mean and S andard De ia ion for Resilience 
Q a  N M . Ma . M S.D. 
Q a  1 487 19.00 40.00 33.56 4.97 
Q a  2 361 18.00 40.00 33.71 5.07 
Q a  3 361 19.00 40.00 33.87 5.00 
 
P fe a  Q a  f L fe Sca e 
T  -b   CCM a  a  a    P a  Q a   L  Sca  
(P QOL), c  c    b ca  a  a  c a  a ac ,  
b , a  c a  a a c  (STS). T  c  a a  c  c a  
c    P QOL a  a c  a ab ; ,  a a    a ca ca  
a   c   ac  ca  a  a   c   22   c a  a  , 23  
41 a  a , a  42 a   a  ,  a b  c  a   ac  c   10 
 50. W    c  a   a ,  P QOL a a    
c   a  c   - c  (S  Tab  7). M a  c  ac  a   a   
   a , ca  a    a  a ac ; , c  
    a  a . CCM a  c    b  ca    P QOL 
  ac ,  a  a a  b    c     a   
  a a   . F a , c    c a  a a c  ca   
 ac  a  a ,  a        a a ca  
  a b         a a    









Means and S andard De ia ions for Well-being 
Va ab  N Ra  M . Ma . M S.D. 
Q1 C a   493 37.45 24.26 61.71 50.35 9.32 
Q1 B  493 43.86 35.49 49.64 49.64 9.49 
Q1 S c a   
T a a c S  
490 42.03 34.10 76.13 49.38 8.92 
Q2 C a  359 38.52 23.67 62.19 50.94 9.03 
Q2 B  360 39.79 35.62 74.41 49.01 9.06 
Q2 S c a   
T a a c S  
360 54.98 34.53 89.51 49.39 9.48 
Q3 C a  358 41.27 20.91 62.19 50.23 9.54 
Q3 B  360 46.25 35.62 81.87 50.25 10.16 
Q3 S c a   
T a a c S  
357 54.98 34.53 89.51 50.16 5.00 
 
Anal sis for Research Questions 
R a c    a , C   a  a  , a   c   
c , b , c a  a a c  (STS), a  c a  a   b  
CCM    c  a  a      a ?   T  a  
 c  ,  a c   Q a  1 a a  a  c  b  CCM 
   c  a  a      a  b  c c  a 
-  a c ca  a   a a   ac   a ab -- c , 
c a  a ac , b , a  c a  a a c . W  a  , a  








   . T    a a  a   c   a c  a ab   a  
 c  a ab  (P c , 2003, . 9).  
R a c    a , C   a  a  ,  c  a  -
b --  b , c a  a ac , a   STS-- c  c a    
a c a    c    c  c a    a c a  a  
a ? T  a   c  ,  a c  c a  Q a  2  Q a  3 a a 
 a  a  c a   c  a  -b  b  c c  a -  a c ca  
a    ac   a ab -- c , c a  a ac , b , a  
c a  a a c . S a    1, a  ca  a   a   c  
a ab    1 a     2, c   a a c  ac   3, a   4 
c  a  c  c a .  
B    , a       
a    acc a  c , a       a a, a  a   
 a ab  a  a a     a ab   b  a a . F  
a ab  a   a   a , ac  a      
c c    c  a c  . T      ac   a  a  
; c  c    ,  b  c a  a ac , b , 
a  c a  a a c . F a , a  c a a   ac  c  a ab  a  
     a  a ca  ca c . 
Te  f A  
T     a a c ca   a a  c     a   
a  a  a   c c   c c a ca   a  a a . W   a   








c   c   a  c c    a a, c     a  a ,  
c  a a  a a . D a c  a         a  
c  a  a  ca    a .  
T    a  a   a c    a c  c  
a ab  a     c  a ab  a  c  b   c   ca ca . 
T , a c   a      , a   c  a ab  
c   c , c a  a ac , b , a  STS  a  c . 
F ,  c  a ab   a , , a  a    1 a  a , , 
c   a a c , a  a  c    2,  a  c a  a  ca ca , 
c   a a   a   a  . T    a    
 S a ca  P c  a  S c  S  (SPSS) a  a  I c  S a c  
a   c  a a   acc ac  a   a   a a    . Eac   
      a a  a     a a .  
A    a   b a    a    a   
c  ,  c    b a . A c a  a a   
 a   0  4  c  b    D b -Wa  a c. A  c  a ab   
 1   a  c   a  a   ba    D b -Wa  
a c  1.57  c , 1.65  c a  a ac , a  1.20  b . A a c 
 .003 a    c a  a a c ,  a a  c a  b  
a . S a ,  a c   2,  a  c   a  ba    
D b -Wa  a c  1.45  c , 1.30  c a  a ac , 0.541  








A     a , a  a     c a c  b  
   a  a a   a a  c  a . T    b  
a a  a  b   c  a  c  a ab . H c a c  a  
a   a  a  a a c    a    c  a ab . T  a  a   
ca     a ba  a      a   c a    c  a . 
R   ac  a ab   a c       F  1  c , 
F  2  c a  a ac , F  3  b , a  F  4  c a  a a c 
.  T  a  a  a c a   a c   2 a  a   F  5  
c ,  F  6 c a  a ac , F  7  b , F  8  c a  
a a c .   
Figure 1 












Figure 2  
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Figure 3 
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Figure 5 
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Figure 7 
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B ca   c  a ab  a  ca ca  a   ca  a  c   
  b  a  a   a c   1, L   a  c c  
a   c a c   a  c  a ab  b  c  a ab . T   
 a a c  a    a a c    c  c   b  a a  a  a  
    c  a ab . M a  c  a     ca c a , a  a  
a a  0.05 a     a .  
T    L '    c  a   ca , F(23, 463) = 0.99, p = .471, 
 c a  a ac , F(23, 469) = 0.83, p = .694,  b , F(23, 469) = 1.4, p = .694. 
H , L '    c a  a a c  a  ca , F(23, 466) = 1.54, p 
= .053, ca  a   a     a a c  a  a   STS. M  
a , STS a    c   a c ca   a a . O c  a ab  
 a c   2   a  a    a    a    








b , F(63, 658) = 0.94, p = .613, c a  a ac , F(63, 658) = 1.08, p = .326; a  
STS, F(63, 648) = 0.82, p = .840. 
A      c   c a , a  a   c  
a ab    c a    a . Va a c  I a  Fac  (VIF ) a  a  
 ca   c  a ab  a  a  a  a     c , 
ca    a  b  b a . F , T a c  b  0.2 ca  
c a , ca  a   a ab   c c    ab . A  
c   a c   1 a  VIF   a  5, a  T a c  a  a  .02, a  
   a  (S  Tab  8).  
Table 8 
Variance Infla ion Fac ors for Each S ep for Research Q es ion 1 
Va ab   T a c  VIF 
R c     
 S  1    
  A  ca   1.000 1.000 
 S  2    
  A  ca   0.990 1.001 
  G   0.990 1.001 
 S  3    
  A  ca   0.998 1.002 
  G   0.999 1.002 
  T a    0.999 1.001 
C a      
 S  1    
  A  ca   1.000 1.000 








  A  ca   0.999 1.001 
  G   0.999 1.001 
 S  3    
  A  ca   0.998 1.002 
  G   0.999 1.001 
  T a    0.999 1.001 
B     
 S  1    
  A  ca   1.000 1.000 
 S  2    
  A  ca   0.999 1.001 
  G   0.999 1.001 
 S  3    
  A  ca   0.998 1.002 
  G   0.999 1.001 
  T a    0.999 1.001 
 
 
M c a  a   b   a    c  a ab   a c   
2 a  . A    Tab  9, a  c     a  VIF   a  5, a  
T a c  a  a  .02  c . T  ca  a    c c    














Variance Infla ion Fac ors for Each S ep for Research Q es ion 2 
Va ab   T a c  VIF 
R c     
 S  1    
  A  ca   1.00 1.00 
 S  2     
  A  ca   1.00 1.00 
  G   1.00 1.00 
 S  3     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c    1.00 1.00 
 S  4     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c    0.47 2.15 
  P c  C a   0.47 2.15 
C a      
 S  1    
  A  ca   1.00 1.00 
 S  2     
  A  ca   1.00 1.00 
  G   1.00 1.00 
 S  3     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c    1.00 1.00 
 S  4     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c    0.47 2.15 








 S  1    
  A  ca   1.00 1.00 
 S  2    
  A  ca   1.00 1.00 
  G   1.00 1.00 
 S  3    
  A  ca   1.00 1.00 
  G   1.00 1.00 
  T a    1.00 1.00 
 S  4    
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c    0.47 2.15 
  P c  C a   0.47 2.15 
STS    
 S  1    
  A  ca   1.00 1.00 
 S  2     
  A  ca   1.00 1.00 
  G   1.00 1.00 
 S  3     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c     1.00 1.00 
 S  4     
  A  ca   1.00 1.00 
  G   1.00 1.00 
  A a c     0.47 2.15 
  P c  C a    0.47 2.15 
 
A        ca   a  a  
a c    a  b  c   c  acc ac    . W  
a    a  a  a  ,  a  ca     c , 








 c  a ab   a c   1. F  a c   2,  a  ca   
  c a  a ac  a  b , a  16  c a  a a c   
ca c a  S  a , a   ab  a    a a   b a  
b . Ob a   a S  a  a  c  3.00 acc    C  
a c   c    a a a a , a   ca   a  a ca  c   
    .  
T  a  a    a ,  a   a   a a  
a  b . N a  a  a a   ac    a Q-Q ca  a  
c a   b    a   a a  b . F   a   
ac  c  a ab  a   b   a c   1 (S  F  9, F  10, 
F  11, a  F  12) a  a c   2 (F  13, F  14, F  15, a  F  
16). N a   a      a a ab  a  , c   ca   ac  
.  
Figure 9 
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Figure 11 
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Figure 13 
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Results Research Question 1 
T    a c ca    a        
acc b   c  a    c   a ab ; c , 
c a  a ac , b , a  c a  a a c   c   a  a  
 a . A   a      a c ca     c , 
c a  a ac , a  b    ac  , a  c  . Eac   
  a c ca   a  c a       F-  a   a   a a 








Re e ce F d g   
T  a c ca    c   c  a ab   c  b    
 10-  CD-RISC c     a   F-   S  3, c  c   
a   c  a , a  ca , ca  a   c  a  a  
,  c  c a   c  c   c a    c  . 
H ,  c a  c a     a  a  ( R2 = 0.024), ca   a 2% 
c   (S  Tab  10). S a ,  c     S  2 a  ca . O c  
a a ,  c a  c a     a  a  ( R2 = 0.015), ca   a 1.5% 
c  . A    acc   a ca  a   a a   c  a   F-   
S  1 a   ca . 
Table 10 
Model Comparisons for Variables Predic ing Resilience S d  1 
M  R2 df  df  F p R
2 
S  1 0.004 5 486 2.11 .147 0.002 
S  2 0.019 2 485 4.79 .009 0.015 
S  3 0.030 1 484 5.06 .002 0.024 
No e. Eac  S  a  c a        a c ca   a a . 
W  a   c a  a  b   ac ,   a ca  
ca  c   b  a  a  a ,  c a    a  a   
c   a   a  1.15   a a  a  a . F , acc   c  
a  ca  c  c . Ba    a ,   a    








a a . A , , a   a ca  c   b . T  a     
  a   Tab  11. 
Table 11 
Hierarchical Regression Anal sis for Variables Predic ing Resilience S d  1 
Va ab  B SE 95% CI  p 
   LL UL   
S  1            
    (I c ) 32.71 0.45 31.83 33.58 0.00 < .001 
        A  25-30 1.38 0.59 0.23 2.54 0.13 .019 
        A  31-35 0.07 0.76 -1.42 1.57 0.01 .923 
        A  36-40 1.78 0.80 0.21 3.36 0.11 .027 
        A  41-50 0.52 0.81 -1.08 2.12 0.03 .523 
        A  51 a   2.03 1.05 -0.03 4.10 0.09 .054 
S  2            
    (I c ) 32.23 0.48 31.28 33.17 0.00 < .001 
        A  25-30 1.34 0.59 0.19 2.50 0.13 .022 
        A  31-35 0.05 0.76 -1.44 1.54 0.00 .950 
        A  36-40 1.72 0.80 0.15 3.28 0.11 .032 
        A  41-50 0.56 0.81 -1.03 2.15 0.04 .487 
        A  51 a   2.17 1.05 0.11 4.23 0.10 .039 
       G - Ma  1.16 0.45 0.27 2.05 0.12 .011 
S  3            
    (I c ) 31.88 0.50 30.88 32.87 0.00 < .001 
        A  25-30 1.17 0.59 0.01 2.33 0.11 .047 
        A  31-35 0.01 0.76 -1.48 1.49 0.00 .994 
        A  36-40 1.61 0.80 0.05 3.17 0.10 .044 
        A  41-50 0.51 0.81 -1.07  2.10 0.03 .523 








        G - Ma  1.15 0.45 0.26 2.03 0.11 .011 
        T a  1.02 0.45 0.13 1.91 0.10 .025 
 
We -be g F d g  
C a  a ac  a  a  b     a a   C a  ca  
  P QOL a  a     c  a ab  a   b  a a  
 a  c a  a a c  a  c      a   a   
a   c a c . C a  a ac       
a  acc   a    ca  c  c a  c a  a ac ,   
 a   . T   a    Tab  12. 
Table 12 
Model Comparisons for Variables predic ing Compassion Sa isfac ion S d  1 
M  R2 df  df  F p R
2 
S  1 0.01 1 491 3.92 0.058 0.006 
S  2 0.01 1 490 1.10 0.082 0.006 
S  3 0.01 1 489 0.13 0.163 0.004 
No e. Eac  S  a  c a        a c ca   a a .  
S a   c a  a ac ,  a c ca    c   
c  a ab   b  b     B  ca    P QOL    
. O   F-   S  1, a  a  c , a  a ca  c  
   , ca  a   a  acc   a ca  a   a a   
B  (S  Tab  13). U   a a  R2  0.004,  c a  c a     









Model Comparisons for Variables predic ing B rno  S d  1 
M  R2 df  df  F p R
2 
S  1 0.04 5 487 4.10 .001 0.03 
S  2 0.04 1 486 1.04 .309 0.03 
S  3 0.04 1 485 1.31 .253 0.03 
No e. Eac  S  a  c a        a c ca   a a . 
T  a a   b  a   a   a  a  b    
a  a  18-24  ca   b  c  a    
c a   c c   c a a . T   c   2.87   a a  
 b  b  18-24  25-30, a  a a   c a  a  a  c a ,  51 a  
 a  ca  a      b  a  6.57   a a  c a   
   18-24- a  a  ca  (S  Tab  14).  
Table 14 
Hierarchical Regression Anal sis for Variables Predic ing B rno  S d  1 
Va ab  B SE 95% CI  p 
   LL UL   
S  1            
    (I c ) 52.35 0.83 50.72 53.98 0.00 < .001 
    A  25-30 -2.69 1.10 -4.85 -0.52 -0.13 .015 
    A  31-35 -3.09 1.44 -5.92 -0.26 -0.11 .032 
    A  36-40 -4.64 1.48 -7.55 -1.73 -0.16 .002 
    A  41-50 -4.63 1.53 -7.63 -1.63 -0.15 .003 
    A  51 a   -6.73 1.98 -10.62 -2.84 -0.16 < .001 








    (I c ) 51.98 0.90 50.21 53.76 0.00 < .001 
    A  25-30 -2.71 1.10 -4.88 -0.55 -0.14 .014 
    A  31-35 -3.12 1.44 -5.95 -0.29 -0.11 .031 
    A  36-40 -4.70 1.48 -7.61 -1.79 -0.16 .002 
    A  41-50 -4.60 1.53 -7.60 -1.60 -0.15 .003 
    A  51 a   -6.63 1.98 -10.52 -2.73 -0.16 < .001 
    G - Ma  0.87 0.85 -0.81 2.55 0.05 .309 
S  3            
    (I c ) 51.64 0.95 49.77 53.51 0.00 < .001 
    A  25-30 -2.87 1.11 -5.05 -0.69 -0.14 .010 
    A  31-35 -3.16 1.44 -5.99 -0.33 -0.11 .029 
    A  36-40 -4.79 1.48 -7.70 -1.87 -0.16 .001 
    A  41-50 -4.64 1.53 -7.64 -1.64 -0.15 .003 
    A  51 a   -6.57 1.98 -10.47 -2.68 -0.16 < .001 
    G - Ma  0.87 0.85 -0.81 2.54 0.05 .310 
    T a  0.98 0.86 -0.70 2.67 0.05 .253 
 
Results for Research Question 2 
T  a  a c   , a -  a c ca  a   a  c c  
  a a  c   a ab ; c , c a  a ac , b , a  
c a  a a c ,     a c a   a   c  
a   c  c  c a  c   c  a  -b  c  ab  a , 
, a   a   a a c  a . T  a c  a  a  c  c  
a   c  a       c . W  a  , a  
ca  a   a   c  a ab   1,  2 a  ,  3 a  c   
a a c , a  a  a   4    . R    a c ca  a   








S a   a c   1, ac     a c ca   a  c a    
   F-   a  a a  a  0.05. T  c c       a  
  . 
Re e ce F d g  
T      ac  a ca  ca c   a , , c   
a a c ,  a   c . I   a    a   a   a   a  
  a    c  acc    CD-RISC 10, a  c  b  
a  2 a  3 c   a   c a  a  a  b c a . F   
 ,  a a  ; C   a  a  , c  c   
c a    a c a    c    c  c a  
  a c a  a  a , a   . Sc    ca   
 c a  a a c     (S  Tab  15). 
Table 15 
Model Comparisons for Variables Predic ing Resilience for S d  2 
M  R2 df  df  F p R
2 
S  1 0.003 1 718 2.19 .139 0.002 
S  2 0.003 1 717 1.17 .311 0.000 
S  3 0.006 1 716 1.54 .202 0.002 
S  4 0.008 1 715 1.41 .228 0.002 
No e. Eac  S  a  c a        a c ca   a a . 
We -be g F d g  
C a  a ac  a  a  b     a a   C a  ca  








  a a  a a c ,  c a  Q a  2 a  3,   c  c a   
c a  a ac . S a       a a c  c . R  
ca  a  a  a     a a   b   a  c   c  
c a  a ac  a  a    . A  a   a a   c  
c a  a ac    , a    a ca  ca ; , a  
a   acc    a   a a c . I c a  c a      
a  ( R2 = 0.03)   ca  a  c     3%, a  2% c    a  
( R2 = 0.03). P a   Tab  16  c .  
Table 16 
Model Comparisons for Variables predic ing Compassion Sa isfac ion in S d  2 
M  R2 df  df  F p R
2 
S  1 0.03 5 713 4.96 < .001 0.03 
S  2 0.06 1 712 17.99 < .001 0.02 
S  3 0.06 4 708 0.36 .840 0.00 
S  4 0.06 1 707 0.51 .477 0.00 
No e. Eac  S  a  c a        a c ca   a a . 
C a  a ac  a a   a  a c   a   a , 
  a c  a  c a  a ac  c a  a  a  a  (J   
a ., 2017; Ma   a ., 2013). P c a , c a  a ac  c     
a    a  ca   31-35, ca  a  a  a a  a  a  a , 
c  a  a  b   COVID 19, a  a  a  c  c . D a  
  1, a     c   c a  a ac  a  a  








  c c  a  a  acc    c a c  (S  Tab  17).  
Table 17 
Hierarchical Regression Anal sis, S d  2 Compassion Predic or Variables 
Va ab  B SE 95% CI  p 
   LL UL   
S  1            
    (I c ) 48.12 0.80 46.56 49.69 0.00 < .001 
    A  Ca  25-30 2.26 0.96 0.37 4.16 0.12 .019 
    A  Ca  31-35 1.81 1.15 -0.44 4.07 0.07 .115 
    A  Ca  36-40 4.02 1.39 1.28 6.75 0.12 .004 
    A  Ca  41-50 4.67 1.46 1.81 7.53 0.14 .001 
    A  Ca  51 a   6.98 1.67 3.70 10.26 0.17 < .001 
S  2            
    (I c ) 49.42 0.85 47.76 51.09 0.00 < .001 
    A  Ca  25-30 2.19 0.95 0.31 4.06 0.11 .022 
    A  Ca  31-35 1.93 1.14 -0.30 4.16 0.08 .090 
    A  Ca  36-40 3.96 1.38 1.25 6.66 0.12 .004 
    A  Ca  41-50 4.73 1.44 1.91 7.56 0.14 .001 
    A  Ca  51 a   7.00 1.65 3.75 10.24 0.17 < .001 
    G - Ma  -2.92 0.69 -4.28 -1.57 -0.15 < .001 
S  3            
    (I c ) 50.09 1.10 47.93 52.26 0.00 < .001 
    A  Ca  25-30 2.25 0.96 0.36 4.14 0.12 .020 
    A  Ca  31-35 2.02 1.14 -0.23 4.26 0.08 .079 
    A  Ca  36-40 4.07 1.39 1.34 6.79 0.12 .003 
    A  Ca  41-50 4.75 1.45 1.90 7.59 0.14 .001 
    A  Ca  51 a   7.12 1.66 3.86 10.38 0.17 < .001 








    A a c  2  a  -0.50 1.46 -3.36 2.36 -0.01 .731 
    A a c  3  a  -0.95 0.89 -2.70 0.81 -0.05 .291 
    A a c  N  a  a  -1.15 1.30 -3.71 1.41 -0.04 .378 
    A a c  W  0.31 3.19 -5.95 6.57 0.00 .923 
S  4            
    (I c ) 50.10 1.10 47.94 52.27 0.00 < .001 
    A  Ca  25-30 2.24 0.96 0.35 4.13 0.12 .020 
    A  Ca  31-35 2.02 1.15 -0.23  4.27 0.08 .078 
    A  Ca  36-40 4.06 1.39 1.34  6.79 0.12 .004 
    A  Ca  41-50 4.74 1.45 1.89  7.59 0.14 .001 
    A  Ca  51 a   7.05 1.66 3.78 10.32 0.17 < .001 
    G - Ma  -2.93 0.69 -4.29 -1.56 -0.15 < .001 
    A a c  2  a  -0.50 1.46 -3.36 2.36 -0.01 .732 
    A a c  3  a  -0.27 1.31 -2.84 2.30 -0.01 .838 
    A a c  N  a  a  -1.15 1.31 -3.71  1.41 -0.04 .378 
    A a c  W  0.30 3.19 -5.96 6.56 0.00 .924 
    F  Ma a  -0.82 1.16 -3.09 1.45 -0.04 .477 
No e. Eac  S  a  c a        a c ca   a a . 
T  a c ca    c   c  a ab   b   
a    c a  a ac ,    . T  F-    
c   a a c  a  a a  a a c ,     a ca  ca c . 
O  a  a    ca  c   b ; , c  a a ,   
a a c  a   a ab . I c a  c a      a  ( R2 = 0.06)  
 ca  a  c     6%, a  2% c    a  ( R2 = 0.02). P a   











Model Comparisons for Variables predic ing B rno  in S d  2 
M  R2 df  df  F p R
2 
S  1 0.06 5 715 8.52 < .001 0.06 
S  2 0.08 1 714 15.95 < .001 0.02 
S  3 0.08 4 710 0.78 .537 0.00 
S  4 0.08 1 709 2.12 .146 0.00 
No e. Eac  S  a  c a        a c ca   a a . 
R   a    c a  a ac    a  ca   31-
35,   c a   b   c a   a   a  ,  ca  
c  a  a  c a   a   a   (S  Tab  19). F     
a   a  a  a ab  a   c . G    a   
a   c a  a ac , a  a     b   a  
a .  
Table 19 
Hierarchical Regression Anal sis, S d  2 B rno  Predic or Variables 
Va ab  B SE 95% CI  p 
   LL UL   
S  1            
    (I c ) 52.01 0.81 50.43 53.59 0.00 < .001 
    A  Ca  25-30 -2.13 0.97 -4.04 -0.23 -0.11 .028 
    A  Ca  31-35 -0.58 1.16 -2.85 1.69 -0.02 .615 
    A  Ca  36-40 -5.65 1.40 -8.41 -2.90 -0.17 < .001 








     A  Ca  51+ -7.33 1.68 -10.63 -4.03 -0.18 < .001 
S  2            
    (I c ) 50.77 0.86 49.09 52.45 0.00 < .001 
    A  Ca  25-30 -2.05 0.96 -3.94 -0.16 -0.11 .033 
    A  Ca  31-35 -0.68 1.15 -2.93 1.57 -0.03 .552 
    A  Ca  36-40 -5.59 1.39 -8.31 -2.86 -0.17 < .001 
    A  Ca  41-50 -6.23 1.45 -9.07 -3.38 -0.18 < .001 
     A  Ca  51+ -7.33 1.66 -10.60 -4.07 -0.18 < .001 
     G - Ma  2.77 0.69 1.41 4.13 0.14 < .001 
S  3            
    (I c ) 49.60 1.11 47.43 51.78 0.00 < .001 
    A  Ca  25-30 -1.96 0.97 -3.86 -0.06] -0.10 .043 
    A  Ca  31-35 -0.63 1.15 -2.90 1.63 -0.03 .583 
    A  Ca  36-40 -5.54 1.40 -8.28 -2.80 -0.17 < .001 
    A  Ca  41-50 -6.03 1.46 -8.90 -3.16 -0.17 < .001 
    A  Ca  51 + -7.35 1.67 -10.63 -4.07 -0.18 < .001 
    G - Ma  2.82 0.70 1.46 4.19 0.15 < .001 
    A a c  2  a  1.47 1.46 -1.39 4.33 0.04 .314 
    A a c  3  a  1.36 0.90 -0.41 3.12 0.07 .132 
    A a c  N  a  a  0.87 1.31 -1.70 3.45 0.03 .506 
    A a c  W  3.68 3.21 -2.61 9.98 0.04 .251 
S  4            
    (I c ) 49.59 1.11 47.41 51.76 0.00 < .001 
    A  Ca  25-30 -1.95 0.97 -3.85 -0.04 -0.10 .045 
    A  Ca  31-35 -0.65 1.15 -2.91 1.61 -0.03 .574 
    A  Ca  36-40 -5.53 1.40 -8.27 -2.79 -0.17 < .001 
    A  Ca  41-50 -6.02 1.46 -8.88 -3.16 -0.17 < .001 
    A  Ca  51 + -7.21 1.67 -10.49 -3.93 -0.17 < .001 








    A a c  2  a  1.46 1.46 -1.39 4.32 0.04 .315 
    A a c  3  a  -0.04 1.31 -2.62 2.54 -0.00 .976 
    A a c  N  a  a  0.87 1.31 -1.70 3.45 0.03 .506 
    A a c  W  3.70 3.20 -2.59 9.99 0.04 .249 
    F  Ma a  1.69 1.16 -0.59 3.97 0.09 .146 
 
R       ac  a ca  ca c   a , , c  
 a a c ,  a   c  STS. Sc  ac  Q a  2 a  3   
 c    STS ca    P QOL,  a  CCM    
  a   STS a   a  c . F    , 
 a a  ; C   a  a  , c  c   c a   
 a c a    c    c  c a    
a c a  a  a , a   . Sc    ca    
c a  a a c    . 
Summar   
T  a a    a c ca   a a  a    a  
 a c   c   a  a ac  c  a  a  
c   c c a  c  a . T  a  acc  b  a  a c a  
a a  a c a  a  a  a    -b  a  c . 
A a  a  a  c c  ab    a c a , c  
 a a c   c  a , , a  a c c  c a ca .    
T   a c        c  a  c  
a   - a  c    CCM a   a  a   a  
a a a   c   a  a  . W     ca c  








  b , a  c a  c a  a ac , a     a  a  c  
 acc    a  6%   a a c  ac .  
A  99%  CCM a   a  a   a  a    , 
 c a   a   a a  a a c        
 COVID-19      ca   a a     . 
T  a c    c a   c    a a  a a c   
  a  c  a  -b    ac   c  a . T , 
 c  a c   a    a a ,  a   c a   a a c ,  
  c a  c  a  -b -- c a  c a  a ac , c  
b , a  c  STS. T  a a   a   , a     
ca  c   c   a    a a   c a  a   
c . W  a      b , c a  a , a  
c a  a a c     a     ,    
ca c    a  a ,  a a ,   a  c   acc    
a  5%   a a c . Sc  ca  a    c  a   b c a , 









 Chapter 5 
Implications, Limitations, and Recommendations 
C c a  c  a  c   a c a    a   c  
 a , , a   a  a  a  a a   b  b   a a   
c a  a a , a   c  a  a   . Ma a  a  b    
    a a  a  ca  c :  ca , c  a  ab  a a  (CSAM), a  
c , c   a c c , a   a   a  a  ac ,  
a a a, a  a  acc  (R b , 2016; Ca a , 2019; R , 2018). A   
a  a  a  100,000 c c a  c  a  ba  (C , 2014),  ca  
c     a  a  c      c c ,  
a  a a  c c   a   c     a  a  
  a a  a a     - a  . L a  a    
  a  a  a    a  a  a  a  a    
 c a  a  a  c a  a a c  (Ba  & K a , 2006; R  & 
B c , 2014),  a   a  c  a   c  CCM a .   
Therefore, this study aimed to measure the effectiveness of a resiliency training program 
specifically designed to aid CCM workers in managing the stressors of their unique work. 
Resilience programs have historically reported success in moderating the adverse effects of stress 
in the workplace and increase resiliency by instructing adaptational coping skills correlated with 
resilience outcomes (Rees et al., 2015; Li et al., 2018; Bajaj & Pande, 2016; Joyce, 2018a). The 
program under review differentiates from traditional programs by providing programming 
weekly through the workplace lifespan and was instructed by licensed mental health 








pandemic, and strictly online the following months after March of 2020, indicating an increased 
benefit by continuous support from professionals to aid content moderators daily in managing 
their workflow. 
J a  c  a  R b  (2018) a  N  (2020)  a   a  a   
  c  a  a     PTSD  . W   a  
 bab  ba    a  ,       
 . F  a      , CCM a  c   b  
 a  a  c      a     STS (M = 0.57, SD = 6.60), 
a    b  (M = 33.20, SD = 5.58), a  a    c a  
a ac  a     (M = 41.21, SD = 7.17)  c b  c  ac  a   
a . F ,   a    c    c  a  
a   c   a   a  (M = 33.20, SD = 5.58), ca   
a   c  a      c a  PTSD, a  c  a  b  
  a  a   a   PTSD acc   C  a  Da  (2003), a  
 a   c   b  c   STS.  
T   a    a c ca   a a  c c   a    
a c  : 1) C   a  a  , a   c   c , b , 
c a  a a c  (STSS), a  c a  a   b  CCM   
 c  a , a      a ?; 2) C   a  a  , 
 c  c  a  -b -- c a  a ac ,  b , a   STS-- c  
c a    a c a    c    c  c a  
  a c a  a  a ? Q   c   a  a  ,   








F , a c        acc   a  c  
c  c  a  -b  c  b  c a  b    c  
a     a . Q   a   a  c   
c   a a a   a        c a  c  a  
-b   a a      a .  
A a      ca  c  b    a  
c a     a , ca  a  a  ca  a c  c . 
F ,  c     a    c a  c   
c  a    a , a   c a  a  a  a   ca ab   
a a    c c . W  a  -b , ca  c   
 b  a  ,     18-24 a  a  c     b  
a  a    c a . O a , c    a   a  a  
c a . R  a   a c  a   b a  a a  a   a  (S  
 a ., 1999; J   a ., 2017; Ma   a ., 2013).  
A a     a     c a   c   c   -
b    a a   a a   a   c     
. I   a    a  99%  a a   a  a   a  a  
      a a . R    a c      
a  a   c a   c a  b  (R b   a ., 2015; J   a ., 
2013). T a a  a      a a    a a  a  a  
. W  a a  -b ,   c    ,  
ca  c    c c  a  a  . A  a  c a   a , 








a   a  a  a  c a . T  a      b   ca  
 c    a  a  a  a  18-24,   a  a a  a .  
Implications  
W  a ca  ca  c     c  a  -b ,  
 b    ca . W  a  c   a    a  
, a   acc   2.4%  c  a a . S a    ca c a  
 a  a  c ,  a  acc   4.04%   a a c   b  
c . Fac   c  a  a  a    a a   c  c     
a c c . R  58.35%   a  c   a    a  
 c a  c  (  a  10%      ), a  100%    
  c   acc    c a ca . T   ca  a  a a   
 c    c   c a  a , b , a  c a  a a c  a  
c a     b   a    c a  c . T ,   
c    b   b  a  c  a   a  a  c   
 a    ca   a a  a   a    . 
F ,   a  a  c a      45 , 
a a c  a  ca  a  . F     Ja a , a a   a a c  
a  a  6.9% (n = 54), 4.0% (n = 25)  F b a , a  15.5% (n = 95)  Ma c     
b  616 a a . C c a       b  b   
 c c -      a c a a   a  a  a  
a  c a .  
I  c      ,  a a c   a  a    








a ac ,   c   c    a    a a   a a c . 
W        a    a  b   a   
a      a a c  a   a  c  a   c a  c ,  
a  c     c  a  -b  c , a b  a  c   
acc ab  a   c  a ,   a    ac . 
R c a   a  a a  ac  a  a  acc   a  a a   
c  a  c  c  a  -b  c    ac  a  c  a  
a      c . 
F ,  c a ,    b a , b a  a  
c    c   a  a      -b  a  
c a  c , c  a   a  c ac   ac  a a . L a  
 c ac  c ,  a    c     
   a a    a ,  - c  , a  c a  
- cac . I , -b  c   a   c ac     
 a      (Ca  & S c a , 2013). T ,  c a '  
a  a  a  c a  c  a  a  c  c a  c  a  -b  
a   c a  ac  a c a    c c , c  a  c a  , - cac , 
a  . C c a     c  a  -b  a  a    a  
c a    c ac  a  a  a    a   
c a  c  a   a  a . 
F a , a a  ac  a    b       a  
b  (M = 33.20, SD = 5.58); , c  a  b  a b    c  ba  








 c  a     a . M a  a  a c  a  a     
   a   a  a  a  , - a  c c , a  
c a  b   c c  c  a        a  
c a  a   a    a  a  . Pa  a  ca  b  
   a  a   a  a   a   .  
Limitations  
T  a c   a c a  a a, a   acc   a  a a a   
ca ab   c a    CCM a     a  ca , a    
cac  a  ca    a c    ca   a  a .  R ab ,  a  
a bac   c c  a  a  c    c c  a  a   a c   
 c   a . T     ab   a   a   c  
 b  R   a . (2015) a  a   c   c   c .  
F  a  c   c   a a   c  a     
  a    Q a  2 a  Q a  3    ab   b a  ab  
c . T  a c  a   c a  a a  ca  b   a a   
     b    a     a  c  a  
 a    a .  T    a c      a 
a     a ,   a     a c a   
 a  b  a a  . I   b  a    a  a  
 a  a  c     c  a   c    
. 
F a ,   a   a   a  ac   COVID 19 a   








F   ba  a c a    a   a a , a a    
c a  c  a      . T  a  a  acc   
 c a  c   c a  a ac  a  c a   b  c  , a  
   a . T a a    ca ab       a    
 a  c  c   c ca   a  ca  a  c . C ,   
c   a a   a    b , a  c c   ba a c  
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7/30/2020 
_____________ 
Vice President of  ______ 
 
RE: Permission to Conduct Research Study 
 
Dear _____________:  
I am writing to request permission to conduct a research study by the collection of data measuring employee 
resilience and well-being.  I am currently enrolled in the Ph.D. Counselor, Education, and Supervision program 
a  S . Ma  U   Sa  A , a  a   e process of writing my Dissertation. The study is 
 B  a R  W ac : P a   c c a  c  a  a . 
I am requesting to obtain the de-identified data of employees who have completed the 10-item Connor 
Davidson Resilience Scale and the Professional Quality of Life Scale for Quarter 2 and Quarter 3 for 
comparison who work within content moderation positions. All information pertaining to ____. will be de-
    a  a  a a a  b a  rom a _________ with the United States. Scores on 
the assessments will be analyzed to answer the following questions:  
Controlling for age and gender, are there differences in resilience, burnout, secondary traumatic stress (STSS), 
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Controlling for age and gender, do resilience scores and well-being-- compassion satisfaction, low 
burnout, and low STS-- scores increase when requiring participation in weekly resiliency skill development 
courses compared to when participation was voluntary?  
Your approval to conduct this study will be greatly appreciated. Furthermore, I would be happy to answer any 
questions or concerns that you may have at this time. You may contact me at my email address at 
@ a . a .  or by phone at ________. 
If you agree, kindly sign below and return the signed form. Alternatively, kindly submit a signed letter of 




Miriah Steiger, M.A., Doctoral Candidate  
Enclosures 
cc: Dr. Dan Ratliff, Research Advisor, STMU 
 
Approved by: 
____ ________ ________              ______________ ______                __30/7/2020 













































































IRB Policy states, “No individual involved in the conduct and/or supervision of 
the research project shall participate in its review.”  This certifies that Dr. Ratliff, 
the faculty sponsor, did not participate in the IRB review. After the IRB members 
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